Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
21 "Hee Young Shin"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Pediatric cancer
Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group
Kyung Mi Park, Keon Hee Yoo, Seong Koo Kim, Jae Wook Lee, Nack-Gyun Chung, Hee Young Ju, Hong Hoe Koo, Chuhl Joo Lyu, Seung Min Han, Jung Woo Han, Jung Yoon Choi, Kyung Taek Hong, Hyoung Jin Kang, Hee Young Shin, Ho Joon Im, Kyung-Nam Koh, Hyery Kim, Hoon Kook, Hee Jo Baek, Bo Ram Kim, Eu Jeen Yang, Jae Young Lim, Eun Sil Park, Eun Jin Choi, Sang Kyu Park, Jae Min Lee, Ye Jee Shim, Ji Yoon Kim, Ji Kyoung Park, Seom Gim Kong, Young Bae Choi, Bin Cho, Young Tak Lim
Cancer Res Treat. 2022;54(1):269-276.   Published online April 20, 2021
DOI: https://doi.org/10.4143/crt.2021.313
AbstractAbstract PDFPubReaderePub
Purpose
Acute promyelocytic leukemia (APL) is a rare disease in children and there are some different characteristics between children and adult. We aimed to evaluate incidence, clinical characteristics and treatment outcomes of pediatric APL in Korea.
Materials and Methods
Seventy-nine pediatric APL patients diagnosed from January 2009 to December 2016 in 16 tertiary medical centers in Korea were reviewed retrospectively.
Results
Of 801 acute myeloid leukemia children, 79 (9.9%) were diagnosed with APL. The median age at diagnosis was 10.6 years (range, 1.3 to 18.0). Male and female ratio was 1:0.93. Thirty patients (38.0%) had white blood cell (WBC) count greater than 10×109/L at diagnosis. All patients received induction therapy consisting of all-trans retinoic acid and chemotherapy. Five patients (6.6%) died during induction chemotherapy and 66 patients (86.8%) achieved complete remission (CR) after induction chemotherapy. The causes of death were three intracranial hemorrhage, one cerebral infarction, and one sepsis. Five patients (7.1%) suffered a relapse during or after maintenance chemotherapy. The estimated 4-year event-free survival and overall survival (OS) rates were 82.1%±4.4%, 89.7%±5.1%, respectively. The 4-year OS was significantly higher in patients with initial WBC < 10×109/L than in those with initial WBC ≥ 10×109/L (p=0.020).
Conclusion
This study showed that the CR rates and survival outcomes in Korean pediatric APL patients were relatively good. The initial WBC count was the most important prognostic factor and most causes of death were related to serious bleeding in the early stage of treatment.

Citations

Citations to this article as recorded by  
  • Management of Acute Promyelocytic Leukemia at Extremes of Age
    Sabine Kayser, Shannon E. Conneely
    Cancers.2023; 15(14): 3637.     CrossRef
  • Current Challenges of Asian National Children's Cancer Study Groups on Behalf of Asian Pediatric Hematology and Oncology Group
    Chi-kong Li, Purna Kurkure, Ramandeep Singh Arora, Bow Wen Chen, Kirill Kirgizov, Yasuhiro Okamoto, Panya Seksarn, Yongmin Tang, Keon Hee Yoo, Bharat Agarwal, Godfrey C.F. Chan, Rashmi Dalvi, Hiroki Hori, Muhammad Saghir Khan, Alice Yu, Akira Nakagawara
    JCO Global Oncology.2023;[Epub]     CrossRef
  • Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation
    Anna Maria Testi, Mazin Faisal Al-Jadiry, Hasanein Habeeb Ghali, Samaher Abdulrazzaq Fadhil, Amir Fadhil Al-Darraji, Raghad Majid Al-Saeed, Ahmed Hatem Sabhan, Safaa A. Faraj Al-Badri, Wisan Majeed Abed, Najiha Ahmed Ameen, Ruaa Zaki Al-Tameemi, Arabiya I
    Leukemia & Lymphoma.2022; 63(12): 2940.     CrossRef
  • Death due to unsuspected acute myeloid leukaemia: an unusual forensic diagnosis
    Lila Krebs-Drouot, Georgia Karpathiou, Virginie Scolan, Carolyne Bidat-Callet, Baptiste Boyer, Michel Péoc’h
    Forensic Science, Medicine and Pathology.2022; 19(1): 60.     CrossRef
  • Successful Treatment of Isolated Central Nervous System Relapse with Intrathecal Chemotherapy in an Adolescent with Acute Promyelocytic Leukemia
    Haerim Song, Eun Sang Yi
    Clinical Pediatric Hematology-Oncology.2022; 29(2): 70.     CrossRef
  • 8,029 View
  • 231 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
CNS cancer
Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae
Joo Ho Lee, Keun-Yong Eom, Ji Hoon Phi, Chul-Kee Park, Seung Ki Kim, Byung-Kyu Cho, Tae Min Kim, Dae Seog Heo, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Hee Young Shin, Seung Hong Choi, Soon Tae Lee, Sung Hye Park, Kyu-Chang Wang, Il Han Kim
Cancer Res Treat. 2021;53(4):983-990.   Published online January 13, 2021
DOI: https://doi.org/10.4143/crt.2020.1052
AbstractAbstract PDFPubReaderePub
Purpose
We aimed to refine the radiotherapy (RT) volume and dose for intracranial germinoma considering recurrences and long-term toxicities.
Materials and Methods
Total 189 patients with intracranial germinoma were treated with RT alone (n=50) and RT with upfront chemotherapy (CRT) (n=139). All cases were confirmed histologically. RT fields comprised the extended-field and involved-field only for primary site. The extended-field, including craniospinal, whole brain (WB), and whole ventricle (WV) for cranial field, is followed by involved-field boost. The median follow-up duration was 115 months.
Results
The relapses developed in 13 patients (6.9%). For the extended-field, cranial RT dose down to 18 Gy exhibited no cranial recurrence in 34 patients. In CRT, 74 patients (56.5%) showed complete response to chemotherapy and no involved-field recurrence with low-dose RT of 30 Gy. WV RT with chemotherapy for the basal ganglia or thalamus germinoma showed no recurrence. Secondary malignancy developed in 10 patients (5.3%) with a latency of 20 years (range, 4 to 26 years) and caused mortalities in six. WB or craniospinal field rather than WV or involved-field significantly increased the rate of hormone deficiencies, and secondary malignancy. RT dose for extended-field correlated significantly with the rate of hormone deficiencies, secondary malignancy, and neurocognitive dysfunction.
Conclusion
De-intensifying extended-field rather than involved-field or total scheme of RT will be critical to decrease the late toxicities. Upfront chemotherapy could be beneficial for the patients with complete response to minimize the RT dose down to 30 Gy. Prospective trials focused on de-intensification of the extended-field RT are warranted.

Citations

Citations to this article as recorded by  
  • Optimal treatment approach for intracranial germinoma: a systematic review and meta-analysis
    Zhirui Zhou, Jiabing Liu, Qi Yue, Lingxiao Chen, Xiwei Zhang, Xin Lin, Lin Zheng, Enmin Wang, Yang Wang, Ying Mao
    BMC Cancer.2025;[Epub]     CrossRef
  • Distribution and failure patterns of primary central nervous system lymphoma related to the hippocampus: implications for hippocampal avoidance irradiation
    Hyejo Ryu, Xue Li, Tae Hoon Lee, Tae Min Kim, Seung Hong Choi, Chul-Kee Park, Soon Tae Lee, Sung-Hye Park, Jae-Kyung Won, Bum-Sup Jang, Il Han Kim, Joo Ho Lee
    Journal of Neuro-Oncology.2025;[Epub]     CrossRef
  • NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
    Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park
    Acta Neuropathologica Communications.2024;[Epub]     CrossRef
  • Clinical significance of cerebral microbleeds in patients with germinoma who underwent long-term follow-up
    Masayuki Kanamori, Shunji Mugikura, Osamu Iizuka, Naoko Mori, Yoshiteru Shimoda, Ichiyo Shibahara, Rei Umezawa, Keiichi Jingu, Ryuta Saito, Yukihiko Sonoda, Toshihiro Kumabe, Kyoko Suzuki, Hidenori Endo
    Journal of Neuro-Oncology.2024; 170(1): 173.     CrossRef
  • Excluding prepontine cistern from whole ventricle radiotherapy target volume in localized germinoma
    Hyejo Ryu, Joo Ho Lee
    Radiation Oncology Journal.2023; 41(1): 48.     CrossRef
  • Intracranial Germinomas: Diagnosis, Pathogenesis, Clinical Presentation, and Management
    Natalia Kremenevski, Michael Buchfelder, Nirjhar Hore
    Current Oncology Reports.2023; 25(7): 765.     CrossRef
  • Proton therapy for pediatric diencephalic tumors
    Adam J. Grippin, Susan L. McGovern
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Intracranial Germinoma—Association between Delayed Diagnosis, Altered Clinical Manifestations, and Prognosis
    Iwona Jabłońska, Marcin Goławski, Elżbieta Nowicka, Katarzyna Drosik-Rutowicz, Anna Trybus, Rafał Tarnawski, Marcin Miszczyk
    Cancers.2023; 15(10): 2789.     CrossRef
  • Outcomes of intracranial germinoma—A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies
    Kyung-Nam Koh, Ru Xin Wong, Dong-Eun Lee, Jung Woo Han, Hwa Kyung Byun, Hong In Yoon, Dong-Seok Kim, Chuhl Joo Lyu, Hyoung Jin Kang, Kyung Taek Hong, Joo Ho Lee, Il Han Kim, Ji Hoon Phi, Seung-Ki Kim, Tai-Tong Wong, Hsin-Lun Lee, I-Chun Lai, Yu-Mei Kang,
    Neuro-Oncology.2022; 24(8): 1389.     CrossRef
  • Photon versus proton whole ventricular radiotherapy for non‐germinomatous germ cell tumors: A report from the Children's Oncology Group
    David Y. Mak, Zain Siddiqui, Zhihui Amy Liu, Hitesh Dama, Shannon M. MacDonald, Shengjie Wu, Erin S. Murphy, Matthew D. Hall, Victor Malkov, Arzu Onar‐Thomas, Sameera Ahmed, Girish Dhall, Derek S. Tsang
    Pediatric Blood & Cancer.2022;[Epub]     CrossRef
  • Factors Influencing Craniospinal Relapse of Intracranial Germinoma After Complete Remission
    Takao Tsurubuchi, Kei Hara, Shingo Takano, Ai Muroi, Hiroko Fukushima, Masashi Mizumoto, Noriaki Sakamoto, Masahide Matsuda, Hiroyoshi Akutsu, Hideyuki Sakurai, Eiichi Ishikawa
    World Neurosurgery.2022; 166: e325.     CrossRef
  • Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma
    Cristina Ilcus, Horatiu Silaghi, Carmen Emanuela Georgescu, Carmen Georgiu, Anca Ileana Ciurea, Simona Delia Nicoara, Cristina Alina Silaghi
    Journal of Personalized Medicine.2021; 11(7): 661.     CrossRef
  • 11,239 View
  • 359 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Pediatric cancer
Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea
Jung Yoon Choi, Che Ry Hong, Kyung Taek Hong, Hyoung Jin Kang, Seongkoo Kim, Jae Wook Lee, Pil Sang Jang, Nack-Gyun Chung, Bin Cho, Hyery Kim, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Seung Min Hahn, Jung Woo Han, Chuhl Joo Lyu, Eu Jeen Yang, Young Tak Lim, Keon Hee Yoo, Hong Hoe Koo, Hoon Kook, In Sang Jeon, Hana Cho, Hee Young Shin
Cancer Res Treat. 2021;53(4):1184-1194.   Published online January 4, 2021
DOI: https://doi.org/10.4143/crt.2020.289
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Effectiveness and safety of clofarabine (one of the treatment mainstays in pediatric patients with relapsed/refractory acute lymphoblastic leukemia [ALL]) was assessed in Korean pediatric patients with ALL to facilitate conditional coverage with evidence development.
Materials and Methods
In this multicenter, prospective, observational study, patients receiving clofarabine as mono/combination therapy were followed up every 4-6 weeks for 6 months or until hematopoietic stem cell transplantation (HSCT). Response rates, survival outcomes, and adverse events were assessed.
Results
Sixty patients (2-26 years old; 65% B-cell ALL, received prior ≥ 2 regimen, 68.3% refractory to previous regimen) were enrolled and treated with at least one dose of clofarabine; of whom 26 (43.3%) completed 6 months of follow-up after the last dose of clofarabine. Fifty-eight patients (96.7%) received clofarabine combination therapy. Overall remission rate (complete remission [CR] or CR without platelet recovery [CRp]) was 45.0% (27/60; 95% confidence interval [CI], 32.4 to 57.6) and the overall response rate (CR, CRp, or partial remission [PR]) was 46.7% (28/60; 95% CI, 34.0 to 59.3), with 11 (18.3%), 16 (26.7%), and one (1.7%) patients achieving CR, CRp, and PR, respectively. The median time to remission was 5.1 weeks (95% CI, 4.7 to 6.1). Median duration of remission was 16.6 weeks (range, 2.0 to 167.6 weeks). Sixteen patients (26.7%) proceeded to HSCT. There were 24 deaths; 14 due to treatment-emergent adverse events.
Conclusion
Remission with clofarabine was observed in approximately half of the study patients who had overall expected safety profile; however, there was no favorable long-term survival outcome in this study.

Citations

Citations to this article as recorded by  
  • Revolutionizing cancer treatment: ROS-induced apoptosis via nanoformulated alkaloids
    Swathi Putta, Santhosh Kumar Chinnaiyan, Ramadevi Korni, Venkata Radha Gadela
    Journal of Drug Delivery Science and Technology.2025; 104: 106556.     CrossRef
  • Proteomic analysis reveals chromatin remodeling as a potential therapeutical target in neuroblastoma
    Zan Liu, Zitong Zhao, Longlong Xie, Zhenghui Xiao, Ming Li, Yong Li, Ting Luo
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • 3′-O-β-Glucosylation of nucleoside analogues using a promiscuous bacterial glycosyltransferase
    Jonathan P. Dolan, Tessa Keenan, Aisling Ní Cheallaigh, Martin A. Fascione, Gavin J. Miller
    RSC Chemical Biology.2025;[Epub]     CrossRef
  • Opciones para el tratamiento de la recaída en leucemia linfoblástica aguda. Revisión de tema
    Christian Omar Ramos-Peñafiel, Carlos Martínez-Murillo, Daniela Pérez-Sámano, Camila Terreros-Palacios, Adán Germán Gallardo-Rodríguez, Irma Olarte-Carrillo, Adolfo Martínez-Tovar
    Revista Médicas UIS.2024;[Epub]     CrossRef
  • Clofarabine

    Reactions Weekly.2023; 1958(1): 155.     CrossRef
  • Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia
    Sima Jeha, Hiroaki Goto, André Baruchel, Emmanuelle Boëlle-Le Corfec, Christine Geffriaud-Ricouard, Rob Pieters, Hee Young Shin
    Advances in Therapy.2023; 40(12): 5447.     CrossRef
  • Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era
    Shang Mengxuan, Zhou Fen, Jin Runming
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • 8,333 View
  • 200 Download
  • 4 Web of Science
  • 7 Crossref
Close layer
Central nervous system
Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System in Children under the Age of 3 Years
Meerim Park, Jung Woo Han, Seung Min Hahn, Jun Ah Lee, Joo-Young Kim, Sang Hoon Shin, Dong-Seok Kim, Hong In Yoon, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Hee Young Shin, Ji Hoon Phi, Seung-Ki Kim, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Do Hoon Lim, Hyung Jin Shin, Hyery Kim, Kyung-Nam Koh, Ho Joon Im, Seung Do Ahn, Young-Shin Ra, Hee-Jo Baek, Hoon Kook, Tae-Young Jung, Hyoung Soo Choi, Chae-Yong Kim, Hyeon Jin Park, Chuhl Joo Lyu
Cancer Res Treat. 2021;53(2):378-388.   Published online October 28, 2020
DOI: https://doi.org/10.4143/crt.2020.756
AbstractAbstract PDFPubReaderePub
Purpose
Atypical teratoid/rhabdoid tumor (ATRT) is a highly aggressive malignancy with peak incidence in children aged less than 3 years. Standard treatment for central nervous system ATRT in children under the age of 3 years have not been established yet. The objective of this study was to analyze characteristics and clinical outcomes of ATRT in children aged less than 3 years.
Materials and Methods
A search of medical records from seven centers was performed between January 2005 and December 2016.
Results
Forty-three patients were enrolled. With a median follow-up of 90 months, 27 patients (64.3%) showed at least one episode of disease progression (PD). The first date of PD was at 160 days after diagnosis. The 1- and 3-year progression-free survivals (PFS) were 51.2% and 28.5%, respectively. The 1- and 3-year overall survivals were 61.9% and 38.1%, respectively. The 3-year PFS was improved from 0% in pre-2011 to 47.4% in post-2011. Excluding one patient who did not receive any further therapy after surgery, 27 patients died due to PD (n=21), treatment-related toxicity (n=5), or unknown cause (n=1). In univariate analysis, factors associated with higher 3-year PFS were no metastases, diagnosis after 2011, early adjuvant radiotherapy, and high-dose chemotherapy (HDCT). In multivariate analysis, the use of HDCT and adjuvant radiotherapy remained significant prognostic factors for PFS (both p < 0.01).
Conclusion
Aggressive therapy including early adjuvant radiotherapy and HDCT could be considered to improve outcomes of ATRT in children under the age of 3 years.

Citations

Citations to this article as recorded by  
  • Metabolic profiling of patient-derived organoids reveals nucleotide synthesis as a metabolic vulnerability in malignant rhabdoid tumors
    Marjolein M.G. Kes, Francisco Morales-Rodriguez, Esther A. Zaal, Terezinha de Souza, Natalie Proost, Marieke van de Ven, Marry M. van den Heuvel-Eibrink, Jeroen W.A. Jansen, Celia R. Berkers, Jarno Drost
    Cell Reports Medicine.2025; 6(1): 101878.     CrossRef
  • High-throughput screening of FDA-approved drugs identifies colchicine as a potential therapeutic agent for atypical teratoid/rhabdoid tumors (AT/RTs)
    Phongthon Kanjanasirirat, Kedchin Jearawuttanakul, Sawinee Seemakhan, Suparerk Borwornpinyo, Patompon Wongtrakoongate, Suradej Hongeng, Sitthivut Charoensutthivarakul
    RSC Advances.2025; 15(16): 12331.     CrossRef
  • Supratentorial ATRT in a young Infant: Expanding the diagnostic spectrum beyond medulloblastoma
    Ali Msheik, Mohamad Aoun, Youssef Fares
    Interdisciplinary Neurosurgery.2024; 35: 101857.     CrossRef
  • Radiation Therapy Plays an Important Role in the Treatment of Atypical Teratoid/Rhabdoid Tumors: Analysis of the EU-RHAB Cohorts and Their Precursors
    Sabine Frisch, Hanna Libuschewski, Sarah Peters, Joachim Gerß, Katja von Hoff, Rolf-Dieter Kortmann, Karolina Nemes, Stefan Rutkowski, Martin Hasselblatt, Torsten Pietsch, Michael C. Frühwald, Beate Timmermann
    International Journal of Radiation Oncology*Biology*Physics.2024; 119(4): 1147.     CrossRef
  • An adult with recurrent atypical teratoid rhabdoid tumor of the spine
    Antoinette J Charles, Vanessa L Smith, C Rory Goodwin, Margaret O Johnson
    CNS Oncology.2024;[Epub]     CrossRef
  • Dynamic Survival Risk Prognostic Model and Genomic Landscape for Atypical Teratoid/Rhabdoid Tumors: A Population-Based, Real-World Study
    Sihao Chen, Yi He, Jiao Liu, Ruixin Wu, Menglei Wang, Aishun Jin
    Cancers.2024; 16(5): 1059.     CrossRef
  • ESTRO-SIOPE guideline: Clinical management of radiotherapy in atypical teratoid/rhabdoid tumors (AT/RTs)
    Beate Timmermann, Claire Alapetite, Karin Dieckmann, Rolf-Dieter Kortmann, Yasmin Lassen-Ramshad, John H. Maduro, Monica Ramos Albiac, Umberto Ricardi, Damien C. Weber
    Radiotherapy and Oncology.2024; 196: 110227.     CrossRef
  • Development and epigenetic regulation of Atypical teratoid/rhabdoid tumors in the context of cell-of-origin and halted cell differentiation
    Laura Huhtala, Goktug Karabiyik, Kirsi J Rautajoki
    Neuro-Oncology Advances.2024;[Epub]     CrossRef
  • Comparative treatment results of children with atypical teratoid/rhabdoid tumor of the central nervous system in the younger age group
    L. V. Olkhova, O. G. Zheludkova, L. S. Zubarovskaya, A. S. Levashov, A. Yu. Smirnova, Yu. V. Dinikina, Yu. V. Kushel, A. G. Melikyan, S. K. Gorelyshev, M. V. Ryzhova, Yu. Yu. Trunin, A. G. Gevorgyan, O. B. Polushkina, V. E. Popov, L. P. Privalova, N. B. Y
    Russian Journal of Pediatric Hematology and Oncology.2023; 10(1): 11.     CrossRef
  • Current Challenges of Asian National Children's Cancer Study Groups on Behalf of Asian Pediatric Hematology and Oncology Group
    Chi-kong Li, Purna Kurkure, Ramandeep Singh Arora, Bow Wen Chen, Kirill Kirgizov, Yasuhiro Okamoto, Panya Seksarn, Yongmin Tang, Keon Hee Yoo, Bharat Agarwal, Godfrey C.F. Chan, Rashmi Dalvi, Hiroki Hori, Muhammad Saghir Khan, Alice Yu, Akira Nakagawara
    JCO Global Oncology.2023;[Epub]     CrossRef
  • Survival and Malignant Transformation of Pineal Parenchymal Tumors: A 30-Year Retrospective Analysis in a Single-Institution
    Tae-Hwan Park, Seung-Ki Kim, Ji Hoon Phi, Chul-Kee Park, Yong Hwy Kim, Sun Ha Paek, Chang-Hyun Lee, Sung-Hye Park, Eun Jung Koh
    Brain Tumor Research and Treatment.2023; 11(4): 254.     CrossRef
  • Atypical Teratoid/Rhabdoid Tumor in Taiwan: A Nationwide, Population-Based Study
    Yen-Lin Liu, Min-Lan Tsai, Chang-I Chen, Noi Yar, Ching-Wen Tsai, Hsin-Lun Lee, Chia-Chun Kuo, Wan-Ling Ho, Kevin Li-Chun Hsieh, Sung-Hui Tseng, James S. Miser, Chia-Yau Chang, Hsi Chang, Wen-Chang Huang, Tai-Tong Wong, Alexander T. H. Wu, Yu-Chun Yen
    Cancers.2022; 14(3): 668.     CrossRef
  • Atypical Teratoid Rhabdoid Tumor: A Possible Oriented Female Pathology?
    Cinzia Baiano, Rosa Della Monica, Raduan Ahmed Franca, Maria Laura Del Basso De Caro, Luigi Maria Cavallo, Lorenzo Chiariotti, Tamara Ius, Emmanuel Jouanneau, Teresa Somma
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical predictors of survival for patients with atypical teratoid/rhabdoid tumors
    Vismaya S. Bachu, Pavan Shah, Adrian E. Jimenez, Adham M. Khalafallah, Jignesh Tailor, Debraj Mukherjee, Alan R. Cohen
    Child's Nervous System.2022; 38(7): 1297.     CrossRef
  • Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors
    Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, Takahiro Sasaki, Andrea Piunti, Amreena Suri, Jun Watanabe, Kouki Abe, Xingyao He, Hiroaki Katagi, Pankaj Bhalla, Manabu Natsumeda, Lihua Zou, Ali Shilatifard, Rintaro Hashizume
    Molecular Cancer Therapeutics.2022; 21(5): 715.     CrossRef
  • Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors
    Chang Zhang, Hao Li
    Pediatric Investigation.2022; 6(2): 111.     CrossRef
  • The results of multicenter treatment of atypical teratoid/rhabdoid tumors of the central nervous system in children under 3 years
    L. V. Olkhova, O. G. Zheludkova, L. S. Zubarovskaya, A. Yu. Smirnova, Yu. V. Dinikina, Yu. V. Kushel, A. G. Melikyan, S. K. Gorelyshev, M. V. Ryzhova, Yu. Yu. Trunin, E. I. Shults, A. G. Gevorgyan, S. V. Gorbatykh, A. N. Kislyakov, V. E. Popov, L. P. Priv
    Pediatric Hematology/Oncology and Immunopathology.2021; 20(2): 121.     CrossRef
  • 9,421 View
  • 305 Download
  • 14 Web of Science
  • 17 Crossref
Close layer
Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients
Hyery Kim, Hyoung Jin Kang, Kyung Duk Park, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Hack Ki Kim, Jae Min Lee, Jeong Ok Hah, Jun Ah Lee, Young Ho Lee, Sang Kyu Park, Hee Jo Baek, Hoon Kook, Ji Yoon Kim, Heung Sik Kim, Hwang Min Kim, Hee Won Chueh, Meerim Park, Hoi Soo Yoon, Mee Jeong Lee, Hyoung Soo Choi, Hyo Seop Ahn, Yoshifumi Kawano, Ji Won Park, Seokyung Hahn, Hee Young Shin
Cancer Res Treat. 2019;51(1):357-367.   Published online May 14, 2018
DOI: https://doi.org/10.4143/crt.2017.457
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients.
Materials and Methods
Data was collected from 15 hospitals in Korea. Patients who received any anthracyclines, and completed treatment without stem cell transplantation were included. For efficacy evaluation, the incidence of cardiac events and cardiac event-free survival rates were compared. Data about risk factors of secondary malignancies were collected.
Results
Data of total 1,453 cases were analyzed; dexrazoxane with every anthracyclines group (D group, 1,035 patients) and no dexrazoxane group (non-D group, 418 patients). Incidence of the reported cardiac events was not statistically different between two groups; however, the cardiac event-free survival rate of patients with more than 400 mg/m2 of anthracyclines was significantly higher in D group (91.2% vs. 80.1%, p=0.04). The 6-year cumulative incidence of secondary malignancy was not different between both groups after considering follow-up duration difference (non-D, 0.52%±0.37%; D, 0.60%±0.28%; p=0.55). The most influential risk factor for secondary malignancy was the duration of anthracycline administration according to multivariate analysis.
Conclusion
Dexrazoxane had an efficacy in lowering cardiac event-free survival rates in patients with higher cumulative anthracyclines. As a result of multivariate analysis for assessing risk factors of secondary malignancy, the occurrence of secondary malignancy was not related to dexrazoxane administration.

Citations

Citations to this article as recorded by  
  • Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage
    Veronika Keresteš, Jan Kubeš, Lenka Applová, Petra Kollárová, Olga Lenčová-Popelová, Iuliia Melnikova, Galina Karabanovich, Mushtaq M Khazeem, Hana Bavlovič-Piskáčková, Petra Štěrbová-Kovaříková, Caroline A Austin, Jaroslav Roh, Martin Štěrba, Tomáš Šimůn
    Toxicological Sciences.2024; 198(2): 288.     CrossRef
  • Circ-0006332 stimulates cardiomyocyte pyroptosis via the miR-143/TLR2 axis to promote doxorubicin-induced cardiac damage
    Ping Zhang, Yuanyuan Liu, Yuliang Zhan, Pengtao Zou, Xinyong Cai, Yanmei Chen, Liang Shao
    Epigenetics.2024;[Epub]     CrossRef
  • Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines
    Xiaomeng Liu, Shuping Ge, Aijun Zhang
    Children.2024; 11(7): 884.     CrossRef
  • Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines
    Parya Rahimi, Behsheed Barootkoob, Ahmed ElHashash, Arun Nair
    Cureus.2023;[Epub]     CrossRef
  • Inducing a Proinflammatory Response with Bioengineered Yeast Vacuoles with TLR2-Binding Peptides (VacT2BP) as a Drug Carrier for Daunorubicin Delivery
    Wooil Choi, Woo-Ri Shin, Yang-Hoon Kim, Jiho Min
    ACS Applied Materials & Interfaces.2023; 15(35): 41258.     CrossRef
  • Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children
    Luigia Meo, Maria Savarese, Carmen Munno, Peppino Mirabelli, Pia Ragno, Ornella Leone, Mariaevelina Alfieri
    Pharmaceutics.2023; 15(12): 2712.     CrossRef
  • Hyperhomocysteinemia as a Link of Chemotherapy-Related Endothelium Impairment
    Ashot Avagimyan
    Current Problems in Cardiology.2022; 47(10): 100932.     CrossRef
  • Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group
    Eric J. Chow, Richard Aplenc, Lynda M. Vrooman, David R. Doody, Yuan‐Shung V. Huang, Sanjeev Aggarwal, Saro H. Armenian, K. Scott Baker, Smita Bhatia, Louis S. Constine, David R. Freyer, Lisa M. Kopp, Wendy M. Leisenring, Barbara L. Asselin, Cindy L. Schw
    Cancer.2022; 128(4): 788.     CrossRef
  • Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
    Esmée C de Baat, Elvira C van Dalen, Renée L Mulder, Melissa M Hudson, Matthew J Ehrhardt, Frederike K Engels, Elizabeth A M Feijen, Heynric B Grotenhuis, Jan M Leerink, Livia Kapusta, Gertjan J L Kaspers, Remy Merkx, Luc Mertens, Roderick Skinner, Wim J
    The Lancet Child & Adolescent Health.2022; 6(12): 885.     CrossRef
  • Cardiotoxicity After Anthracycline Chemotherapy for Childhood Cancer in a Multiethnic Asian Population
    Varen Zhi Zheng Tan, Nicole Min Chan, Wai Lin Ang, Soe Nwe Mya, Mei Yoke Chan, Ching Kit Chen
    Frontiers in Pediatrics.2021;[Epub]     CrossRef
  • Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study
    Adriana Linares Ballesteros, Roy Sanguino Lobo, Juan Camilo Villada Valencia, Oscar Arévalo Leal, Diana Constanza Plazas Hernández, Nelson Aponte Barrios, Iván Perdomo Ramírez
    Colombia Medica.2021; 52(1): e2034542.     CrossRef
  • Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy
    Claire Fraley, Sarah A. Milgrom, Lavanya Kondapalli, Matthew R. G. Taylor, Luisa Mestroni, Shelley D. Miyamoto
    Children.2021; 8(9): 829.     CrossRef
  • Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
    Valentina K. Todorova, Eric R. Siegel, Yihong Kaufmann, Asangi Kumarapeli, Aaron Owen, Jeanne Y. Wei, Issam Makhoul, V. Suzanne Klimberg
    Translational Oncology.2020; 13(2): 471.     CrossRef
  • Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity
    Petra Kollárová-Brázdová, Anna Jirkovská, Galina Karabanovich, Zuzana Pokorná, Hana Bavlovič Piskáčková, Eduard Jirkovský, Jan Kubeš, Olga Lenčová-Popelová, Yvona Mazurová, Michaela Adamcová, Veronika Skalická, Petra Štěrbová-Kovaříková, Jaroslav Roh, Tom
    The Journal of Pharmacology and Experimental Therapeutics.2020; 373(3): 402.     CrossRef
  • Anthracyclines/cyclophosphamide/etoposide

    Reactions Weekly.2019; 1741(1): 28.     CrossRef
  • Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
    Sarju Ganatra, Anju Nohria, Sachin Shah, John D. Groarke, Ajay Sharma, David Venesy, Richard Patten, Krishna Gunturu, Corrine Zarwan, Tomas G. Neilan, Ana Barac, Salim S. Hayek, Sourbha Dani, Shantanu Solanki, Syed Saad Mahmood, Steven E. Lipshultz
    Cardio-Oncology.2019;[Epub]     CrossRef
  • Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
    Neha Bansal, M. Jacob Adams, Sarju Ganatra, Steven D. Colan, Sanjeev Aggarwal, Rudolf Steiner, Shahnawaz Amdani, Emma R. Lipshultz, Steven E. Lipshultz
    Cardio-Oncology.2019;[Epub]     CrossRef
  • Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2
    Antonis A. Manolis, Theodora A. Manolis, Dimitri P. Mikhailidis, Antonis S. Manolis
    Expert Opinion on Drug Safety.2018; 17(9): 893.     CrossRef
  • 10,449 View
  • 334 Download
  • 19 Web of Science
  • 18 Crossref
Close layer
APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia
Hyery Kim, Heewon Seo, Yoomi Park, Byung-Joo Min, Myung-Eui Seo, Kyung Duk Park, Hee Young Shin, Ju Han Kim, Hyoung Jin Kang
Cancer Res Treat. 2018;50(3):823-834.   Published online September 4, 2017
DOI: https://doi.org/10.4143/crt.2017.351
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Mercaptopurine (MP) is one of the main chemotherapeutics for acute lymphoblastic leukemia (ALL). To improve treatment outcomes, constant MP dose titration is essential to maintain steady drug exposure, while minimizing myelosuppression. We performed two-stage analyses to identify genetic determinants of MP-related neutropenia in Korean pediatric ALL patients.
Materials and Methods
Targeted sequencing of 40 patients who exhibited definite MP intolerance was conducted using a novel panel of 211 pharmacogenetic-related genes, and subsequent analysis was performed with 185 patients.
Results
Using bioinformatics tools and genetic data, four functionally interesting variants were selected (ABCC4, APEX1, CYP1A1, and CYP4F2). Including four variants, 23 variants in 12 genes potentially linked to MP adverse reactions were selected as final candidates for subsequent analysis in 185 patients. Ultimately, a variant allele in APEX1 rs2307486was found to be strongly associated with MP-induced neutropenia that occurred within 28 days of initiating MP (odds ratio, 3.44; p=0.02). Moreover, the cumulative incidence of MP-related neutropenia was significantly higher in patients with APEX1 rs2307486 variants, as GG genotypes were associated with the highest cumulative incidence (p < 0.01). NUDT15 rs116855232 variants were strongly associated with a higher cumulative incidence of neutropenia (p < 0.01), and a lower median dose of tolerated MP throughout maintenance treatment (p < 0.01).
Conclusion
We have identified that APEX1 rs2307486 variants conferred an increased risk of MP-related early onset neutropenia. APEX1 and NUDT15 both contribute to cell protection from DNA damage or misincorporation, so alleles that impair the function of either gene may affect MP sensitivities, thereby inducing MP-related neutropenia.

Citations

Citations to this article as recorded by  
  • Parallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia
    Simonetta I. Gaumond, Karen J. Lee, Peyton V. Warp, Isabella Kamholtz, Emilee M. Dreifus, Joaquin J. Jimenez
    Cancers.2025; 17(7): 1163.     CrossRef
  • Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response
    Ashwin Kamath, Suresh Kumar Srinivasamurthy, Mukta N. Chowta, Sheetal D. Ullal, Youssef Daali, Uppugunduri S. Chakradhara Rao
    Pharmaceuticals.2022; 15(8): 990.     CrossRef
  • The Effect of NUDT15, TPMT, APEX1, and ITPA Genetic Variations on Mercaptopurine Treatment of Pediatric Acute Lymphoblastic Leukemia
    Jae Min Lee, Ye Jee Shim, Do-Hoon Kim, Nani Jung, Jung-Sook Ha
    Children.2021; 8(3): 224.     CrossRef
  • Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT
    Hyery Kim, Seungwon You, Yoomi Park, Jung Yoon Choi, Youngeun Ma, Kyung Tak Hong, Kyung-Nam Koh, Sunmin Yun, Kye Hwa Lee, Hee Young Shin, Suehyun Lee, Keon Hee Yoo, Ho Joon Im, Hyoung Jin Kang, Ju Han Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • NUDT15 polymorphism in healthy children with Bai nationality in Yunnan of China
    Gangling Pu, Yali Wang, Shaoqin Duan, Jingpei Chen, Chunhui Yang, Tingting Cui, Chunlian Fang, Yan Zhou, Han Zhang, Xin Tian
    Pediatrics International.2021; 63(7): 790.     CrossRef
  • A Dual Face of APE1 in the Maintenance of Genetic Stability in Monocytes: An Overview of the Current Status and Future Perspectives
    Gabriela Betlej, Ewelina Bator, Antoni Pyrkosz, Aleksandra Kwiatkowska
    Genes.2020; 11(6): 643.     CrossRef
  • Homozygote CRIM1 variant is associated with thiopurine-induced neutropenia in leukemic patients with both wildtype NUDT15 and TPMT
    Yoomi Park, Hyery Kim, Heewon Seo, Jung Yoon Choi, Youngeun Ma, Sunmin Yun, Byung-Joo Min, Myung-Eui Seo, Keon Hee Yoo, Hyoung Jin Kang, Ho Joon Im, Ju Han Kim
    Journal of Translational Medicine.2020;[Epub]     CrossRef
  • Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology
    Emma C. Bernsen, Melanie M. Hagleitner, Theodorus W. Kouwenberg, Lidwien M. Hanff
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Long-term treatment outcomes of children and adolescents with lymphoblastic lymphoma treated with various regimens: a single-center analysis
    Ho Jung Choi, Juhee Shin, Sunghan Kang, Jin Kyung Suh, Hyery Kim, Kyung-Nam Koh, Ho Joon Im
    BLOOD RESEARCH.2020; 55(4): 262.     CrossRef
  • NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia
    Eun Sang Yi, Young Bae Choi, Rihwa Choi, Na Hee Lee, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Soo-Youn Lee, Hong Hoe Koo
    Cancer Research and Treatment.2018; 50(3): 872.     CrossRef
  • 24,204 View
  • 333 Download
  • 13 Web of Science
  • 10 Crossref
Close layer
ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor
Ji Won Lee, Sung Hye Park, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn
Cancer Res Treat. 2018;50(2):495-505.   Published online May 22, 2017
DOI: https://doi.org/10.4143/crt.2016.577
AbstractAbstract PDFPubReaderePub
Purpose
In this study, anaplastic lymphoma kinase (ALK) mutation and amplification, ALK protein expression, loss of the nuclear alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein, and telomerase reverse transcriptase (TERT) protein expressionwere studied to investigate potential correlations between these molecular characteristics and clinical features or outcomes in neuroblastoma.
Materials and Methods
Seventy-two patients were enrolled in this study. Polymerase chain reaction amplification and direct sequencing were used for mutation analysis. ALK and MYCN amplifications were detected by fluorescence in situ hybridization. Protein expressionwas evaluated by immunohistochemical (IHC) staining.
Results
ALK mutation was found in only two patients (4.1%); ALK amplification was not detected. ALK positivity, loss of nuclear ATRX protein, TERT positivity by IHC were detected in 40 (55.6%), nine (13.0%), and 42 (59.2%) patients, respectively. The incidence of ALK expression increased in accordance with increasing tumor stage (p=0.001) and risk group (p < 0.001). The relapse rate was significantly higher in ALK+ patients compared to that of other patients (47.5% vs. 11.3%, p=0.007). However, there was no significant difference in relapse rate when the survival analysis was confined to the high-risk patients.
Conclusion
Although ALK mutation was rare and no amplification was observed, ALK protein expression was found in a significant number of patients and was correlated with advanced stage and high-risk neuroblastoma. ALK protein expression could be considered as a marker related to the aggressive neuroblastoma, but it was not the independent prognostic factor for the outcome.

Citations

Citations to this article as recorded by  
  • Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features
    Thu Dang Anh Phan, Thao Quyen Nguyen, Nhi Thuy To, Thien Ly Thanh, Dat Quoc Ngo
    Journal of Pathology and Translational Medicine.2024; 58(1): 29.     CrossRef
  • Multi-omics revealed that ELAVL3 regulates MYCN in neuroblastoma via immunogenic cell death: Risk stratification and experimental research
    Peng Hong, Zaihong Hu, Jie Lin, Kongkong Cui, Zhiqiang Gao, Xiaomao Tian, Qinlin Shi, Tao Lin, Guanghui Wei
    International Journal of Biological Macromolecules.2024; 282: 137045.     CrossRef
  • Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in MYCN Non-Amplified Neuroblastoma
    Manli Zhao, Weizhong Gu, Fei Liu, Lihua Yu, Yan Shu, Lei Liu, Jiahui Hu, Yang Liu, Hongfeng Tang, Jianhua Mao
    Pediatric and Developmental Pathology.2023; 26(2): 124.     CrossRef
  • ALKGene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples
    Neha Bhardwaj, Manish Rohilla, Upasana Gautam, Amita Trehan, Deepak Bansal, Nandita Kakkar, Radhika Srinivasan
    American Journal of Clinical Pathology.2023;[Epub]     CrossRef
  • Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR
    Manli Zhao, Zhonghai Guan, Liang Gong, Fei Liu, Weizhong Gu, Lei Liu, Kewen Jiang, Jiabin Cai, Chunyue Feng, Chik Hong Kuick, Kenneth Tou En Chang, Jinhu Wang, Hongfeng Tang, Minzhi Yin, Jianhua Mao
    Pathology.2023; 55(7): 958.     CrossRef
  • Interactions of Butyrylcholinesterase with Neuroblastoma-associated Oncoproteins
    Janina Baranowska-Kortylewicz, Zbigniew P. Kortylewicz, Erin M. McIntyre, John G. Sharp, Don W. Coulter
    Current Enzyme Inhibition.2023; 19(2): 109.     CrossRef
  • Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma
    Trupti Trivedi, Kinjal Panchal, Neha Bhalala, Priti Trivedi, Harsha Panchal
    World Neurosurgery.2022; 159: e48.     CrossRef
  • ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma
    Dinesh Babu Somasundaram, Sheeja Aravindan, Nandita Gupta, Zhongxin Yu, Ashley Baker, Natarajan Aravindan
    World Journal of Pediatrics.2022; 18(4): 285.     CrossRef
  • Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHE Deletion on the Neuroblastoma Growth In Vitro and In Vivo
    Janina Baranowska-Kortylewicz, Zbigniew P. Kortylewicz, Erin M. McIntyre, John G. Sharp, Don W. Coulter
    Journal of Pediatric Hematology/Oncology.2022; 44(6): 293.     CrossRef
  • Differential Impact of ALK Mutations in Neuroblastoma
    Tara O'Donohue, Nitya Gulati, Audrey Mauguen, Brian H. Kushner, Neerav Shukla, M. I. Rodriguez-Sanchez, Nancy Bouvier, Stephen Roberts, Ellen Basu, Nai-Kong Cheung, Shakeel Modak
    JCO Precision Oncology.2021; (5): 492.     CrossRef
  • The challenge of defining “ultra‐high‐risk” neuroblastoma
    Daniel A. Morgenstern, Rochelle Bagatell, Susan L. Cohn, Michael D. Hogarty, John M. Maris, Lucas Moreno, Julie R. Park, Andrew D. Pearson, Gudrun Schleiermacher, Dominique Valteau‐Couanet, Wendy B. London, Meredith S. Irwin
    Pediatric Blood & Cancer.2019;[Epub]     CrossRef
  • ALK in Neuroblastoma: Biological and Therapeutic Implications
    Ricky Trigg, Suzanne Turner
    Cancers.2018; 10(4): 113.     CrossRef
  • 10,131 View
  • 364 Download
  • 10 Web of Science
  • 12 Crossref
Close layer
Incidence and Survival of Childhood Cancer in Korea
Hyeon Jin Park, Eun-Kyeong Moon, Ju Young Yoon, Chang-Mo Oh, Kyu-Won Jung, Byung Kiu Park, Hee Young Shin, Young-Joo Won
Cancer Res Treat. 2016;48(3):869-882.   Published online January 21, 2016
DOI: https://doi.org/10.4143/crt.2015.290
AbstractAbstract PDFPubReaderePub
Purpose
An epidemiologic study of childhood cancer would provide useful information on cancer etiology and development of management guidelines.
Materials and Methods
Data from the Korea National Cancer Incidence Database were used to examine the incidence and survival of cancer in patients aged 0-14 years. Patients were grouped according to the International Classification of Childhood Cancer, 3rd edition. Age-specific and age-standardized incidences per million and estimated annual percentage change (APC) were calculated by sex and age. Five-year relative survival was calculated for four periods from 1993 to 2011.
Results
The study comprised 15,113 patients with malignant neoplasms. Age-standardized incidence rates for all cancers were 134.9 per million children in 1999-2011 and 144.0 and 124.9 per million for males and females, respectively (M/F ratio, 1.2; p < 0.05). The highest incidences were observed for ‘leukemias, myeloproliferative diseases, and myelodysplastic diseases’ (group I) (46.4), ‘central nervous system neoplasms’ (group III) (18.3), and ‘lymphomas and reticuloendothelial neoplasms’ (group II) (13.4). Age-standardized incidence increased from 117.9 in 1999 to 155.3 in 2011, with an APC of 2.4% (95% confidence interval, 2.1 to 2.7). There was a significant increase of APC in ‘neuroblastoma and other peripheral nervous cell tumors’ (group IV) (5.6%) and ‘other malignant epithelial neoplasms and malignant melanomas’ (group XI) (5.6%). The 5-year relative survival rate for all childhood cancers improved significantly from 56.2% (1993-1995) to 78.2% (2007-2011) (males, 56.7% to 77.7%; females, 55.5% to 78.8%).
Conclusion
This study provides reliable information on incidence and survival trends for childhood cancer in Korea.

Citations

Citations to this article as recorded by  
  • Epidemiology and clinical features of childhood malignant solid tumors in a single center in southwest China over 24 years
    Ting Li, Xiangpan Kong, Dawei He
    BMC Pediatrics.2025;[Epub]     CrossRef
  • Pediatric Dentistry Consultations at Seoul Asan Medical Center for the Last 3 Years
    Hyeri Yang, Soyeon Bak, Hyeonheon Lee
    THE JOURNAL OF THE KOREAN ACADEMY OF PEDTATRIC DENTISTRY.2025; 52(1): 21.     CrossRef
  • Parent caregivers’ preferences and satisfaction with currently provided childhood cancer survivorship care
    Keun Hye Jeon, Dong Wook Shin, Ji Won Lee, Hee Jo Baek, Nack-Gyun Chung, Ki Woong Sung, Yun-Mi Song
    Journal of Cancer Survivorship.2024; 18(2): 617.     CrossRef
  • Subjective Toxicity Profiles of Children With Cancer During Treatment
    Haishan Ruan, Jiwen Sun, Kangjia Zhao, Mengxue He, Changrong Yuan, Lijuan Fu, Nanping Shen
    Cancer Nursing.2024; 47(1): E1.     CrossRef
  • Effects of Korean red ginseng on T-cell repopulation after autologous hematopoietic stem cell transplantation in childhood cancer patients
    Kyung Taek Hong, Yeon Jun Kang, Jung Yoon Choi, Young Ju Yun, Il-Moo Chang, Hee Young Shin, Hyoung Jin Kang, Won-Woo Lee
    Journal of Ginseng Research.2024; 48(1): 68.     CrossRef
  • Risk Factors for Treatment-Related Amenorrhea in Female Survivors of Childhood and Adolescent Cancer: 10-Year Experiences at Oncofertility Clinic in Korean Tertiary Center
    Soo Jin Park, Jung Yoon Choi, Hyoung Jin Kang, Yun Jeong Lee, Young Ah Lee, Ji Yeon Han, Sung Woo Kim, Hoon Kim, Seung-Yup Ku
    Journal of Adolescent and Young Adult Oncology.2024; 13(1): 162.     CrossRef
  • Ten-Year Trends of Hematopoietic Stem Cell Transplantation in Korean Pediatric Cancer from the National Health Insurance Claims Data
    Hyery Kim, Hwa Jung Kim, Youngjun Jo, Su Hyun Yoon, Young Kwon Koh, Sunghan Kang, Kyung-Nam Koh, Ho Joon Im
    Cancer Research and Treatment.2024; 56(1): 294.     CrossRef
  • Association of Insulin-like Growth Factor-1 with Bone Mineral Density in Survivors of Childhood Acute Leukemia
    Seulki Kim, Jae Won Yoo, Jae Wook Lee, Min Ho Jung, Bin Cho, Byng-Kyu Suh, Moon Bae Ahn, Nack-Gyun Chung
    Cancers.2024; 16(7): 1296.     CrossRef
  • Trends in incidence and survival of childhood cancers in Khon Kaen, Thailand (2000–2019): a population-based Khon Kaen Cancer Registry study
    Chanaporn Pinsuwan, Chalongpon Santong, Su-on Chainansamit, Patcharee Komvilaisak, Prapassara Sirikarn, Surachai Phimha, Kunanya Suwannaying
    BMC Public Health.2024;[Epub]     CrossRef
  • VisTA: vision transformer-attention enhanced CNN ensemble for optimized classification of acute lymphoblastic leukemia benign and progressive malignant stages
    Hasmitha Krishna Nunna, Ali Altable, Pallavi Gundala, Prasanna Kumar Rangarajan
    International Journal of Information Technology.2024;[Epub]     CrossRef
  • A POPULATION-BASED STUDY ON THE DEMOGRAPHIC AND CLINICAL PARAMETERS AMONG CHILDHOOD LEUKEMIA SURVIVAL
    Nabihah Ali, Saihpudin Saupin, Balqis Bahtiar, Shamsul Bahari Shamsudin
    The Indonesian Journal of Public Health.2024; 19(2): 226.     CrossRef
  • Prevalence and Risk Factors of Metabolic Syndrome Components in Childhood Cancer Survivors
    Hye Young Jin, Jun Ah Lee, Meerim Park, Hyeon Jin Park
    Journal of Adolescent and Young Adult Oncology.2023; 12(2): 224.     CrossRef
  • Epidemiologic and Clinical Outcomes of Pediatric Renal Tumors in Korea: A Retrospective Analysis of The Korean Pediatric Hematology and Oncology Group (KPHOG) Data
    Kyung-Nam Koh, Jung Woo Han, Hyoung Soo Choi, Hyoung Jin Kang, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Kyung Taek Hong, Jung Yoon Choi, Sung Han Kang, Hyery Kim, Ho Joon Im, Seung Min Hahn, Chuhl Joo Lyu, Hee-Jo Baek, Hoon Kook, Kyung Mi Pa
    Cancer Research and Treatment.2023; 55(1): 279.     CrossRef
  • The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis
    Nader Salari, Hooman Ghasemi, Reza Fatahian, Kamran Mansouri, Sadat Dokaneheifard, Mohammad hossain Shiri, Mahvan Hemmati, Masoud Mohammadi
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Medulloblastoma: Current Perspectives and Recent Advances
    Jung Yoon Choi
    Brain Tumor Research and Treatment.2023; 11(1): 28.     CrossRef
  • Self-reported physical activity behaviors of childhood cancer survivors: comparison to a general adolescent population in Korea
    Yohwan Yeo, Ji Won Lee, Dong Wook Shin, Hee Jo Baek, Nack-Gyun Chung, Ki Woong Sung, Yun-Mi Song
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • Current Status and Physicians’ Perspectives of Childhood Cancer Survivorship in Korea: A Nationwide Survey of Pediatric Hematologists/Oncologists
    Ji Won Lee, Yohwan Yeo, Hee Young Ju, Hee Won Cho, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Su-Min Jeong, Dong Wook Shin, Hee Jo Baek, Hoon Kook, Nack-Gyun Chung, Bin Cho, Young Ae Kim, Hyeon Jin Park, Yun-Mi Song
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Antifungal Drug-Drug Interactions with Commonly Used Pharmaceutics in European Pediatric Patients with Acute Lymphoblastic Leukemia
    Beata Sienkiewicz-Oleszkiewicz, Małgorzata Salamonowicz-Bodzioch, Justyna Słonka, Krzysztof Kałwak
    Journal of Clinical Medicine.2023; 12(14): 4637.     CrossRef
  • Incidence and pattern of childhood cancer in Addis Ababa, Ethiopia (2012–2017)
    Amanuel Belay, Ahmed Ali, Wondimu Ayele, Mathewos Assefa, Ahmedin Jemal, Eva J. Kantelhardt
    BMC Cancer.2023;[Epub]     CrossRef
  • Analysis of acute leukemia complications in children at the disease onset and during induction
    E. S. Lygina, E. A. Andreeva, М. A. Rusina, Yu. V. Dinikina
    Oncohematology.2023; 18(4): 213.     CrossRef
  • Treatment outcome and prognostic factors in relapsed pediatric acute myeloid leukemia
    Jung Hwan Lee, Hee Young Ju, Ju Kyung Hyun, So Jin Kim, Hee Won Cho, Jae Kyung Lee, Ji Won Lee, Ki Woong Sung, Keon Hee Yoo
    Blood Research.2023; 58(4): 181.     CrossRef
  • Factors associated with the comprehensive needs of caregivers of childhood cancer survivors in Korea
    Keun Hye Jeon, In Young Choi, In Young Cho, Dong Wook Shin, Ji Won Lee, Hee Jo Baek, Nack-Gyun Chung, Ki Woong Sung, Yun-Mi Song
    Journal of Cancer Survivorship.2022; 16(5): 948.     CrossRef
  • Social inequalities in treatment receipt for childhood cancers in Ireland: A population‐based analysis
    Michal Molcho, Audrey A. Thomas, Paul M. Walsh, Roderick Skinner, Linda Sharp
    International Journal of Cancer.2022; 150(6): 941.     CrossRef
  • Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
    Hee Young Ju, Meerim Park, Jun Ah Lee, Hyeon Jin Park, Seog Yun Park, June Hyuk Kim, Hyun Guy Kang, Hee Chul Yang, Byung-Kiu Park
    Cancer Research and Treatment.2022; 54(2): 563.     CrossRef
  • Spiritual pain as part of the hospitalization experience of children and adolescents with acute lymphoblastic leukemia: A phenomenological study
    Encarna Gomez-Gamboa, Olga Rodrigo-Pedrosa, Maria Angeles Saz Roy, Ana Gomez-Rodriguez, Anna Negre Loscertales, Montserrat Puig Llobet
    European Journal of Oncology Nursing.2022; 58: 102141.     CrossRef
  • Favorable outcome of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with nonmetastatic osteosarcoma and low-degree necrosis
    Kyung Taek Hong, Hyun Jin Park, Bo Kyung Kim, Hong Yul An, Jung Yoon Choi, Jung-Eun Cheon, Sung-Hye Park, Han-Soo Kim, Hyoung Jin Kang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Trends in Pediatric Thyroid Cancer Incidence, Treatment, and Clinical Course in Korea During 2004–2016: A Nationwide Population-Based Study
    Young Ah Lee, Hyo Ri Yun, Juneyoung Lee, Hyemi Moon, Choong Ho Shin, Sin Gon Kim, Young Joo Park
    Thyroid.2021; 31(6): 902.     CrossRef
  • Cancer Incidence and Survival among Adolescents and Young Adults in Korea: An Update for 2016
    Meerim Park, Jiwon Lim, Jun Ah Lee, Byung Kiu Park, Kyu-Won Jung, Young-Joo Won, Hyeon Jin Park
    Cancer Research and Treatment.2021; 53(1): 32.     CrossRef
  • Treatment Outcomes of Pediatric Acute Myeloid Leukemia in the Yeungnam Region: A Multicenter Retrospective Study of the Study Alliance of Yeungnam Pediatric Hematology–Oncology (SAYPH)
    Jae Min Lee, Eu Jeen Yang, Kyung Mi Park, Young-Ho Lee, Heewon Chueh, Jeong Ok Hah, Ji Kyoung Park, Jae Young Lim, Eun Sil Park, Sang Kyu Park, Heung Sik Kim, Ye Jee Shim, Jeong A. Park, Eun Jin Choi, Kun Soo Lee, Ji Yoon Kim, Young Tak Lim
    Children.2021; 8(2): 109.     CrossRef
  • Patterns and trends of cancer incidence in children and adolescents in China, 2011–2015: A population‐based cancer registry study
    Kexin Sun, Rongshou Zheng, Siwei Zhang, Hongmei Zeng, Shaoming Wang, Ru Chen, Wenqiang Wei, Jie He
    Cancer Medicine.2021; 10(13): 4575.     CrossRef
  • Identification of a Seven-lncRNA-mRNA Signature for Recurrence and Prognostic Prediction in Relapsed Acute Lymphoblastic Leukemia Based on WGCNA and LASSO Analyses
    Haiyan Qi, Long Chi, Xiaogang Wang, Xing Jin, Wensong Wang, Jianping Lan, Ulises Urzua
    Analytical Cellular Pathology.2021; 2021: 1.     CrossRef
  • Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea
    Jung Yoon Choi, Che Ry Hong, Kyung Taek Hong, Hyoung Jin Kang, Seongkoo Kim, Jae Wook Lee, Pil Sang Jang, Nack-Gyun Chung, Bin Cho, Hyery Kim, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Seung Min Hahn, Jung Woo Han, Chuhl Joo Lyu, Eu Jeen Yang, Young Tak Li
    Cancer Research and Treatment.2021; 53(4): 1184.     CrossRef
  • Living with the Late Effects of Childhood Cancer Treatment: A Descriptive Qualitative Study
    Hye Chong Hong, Ari Min, Sungkyoung Choi
    International Journal of Environmental Research and Public Health.2021; 18(16): 8392.     CrossRef
  • Profiling and potential cancer risk assessment on children exposed to PAHs in playground dust/soil: a comparative study on poured rubber surfaced and classical soil playgrounds in Seoul
    Abhrajyoti Tarafdar, Min-Ju Oh, Quynh Nguyen-Phuong, Jung-Hwan Kwon
    Environmental Geochemistry and Health.2020; 42(6): 1691.     CrossRef
  • Neurocognitive impairment in Asian childhood cancer survivors: a systematic review
    Liwen Peng, Perri Pui-Yan Yam, Lok Sum Yang, Satomi Sato, Chi Kong Li, Yin Ting Cheung
    Cancer and Metastasis Reviews.2020; 39(1): 27.     CrossRef
  • Pediatric Adenocarcinoma in Korea: A Multicenter Study
    Hee-Beom Yang, Jung-Man Namgoong, Ki Hoon Kim, Dae Yeon Kim, Jinyoung Park, Hyun Beak Shin, Joong Kee Youn, Sanghoon Lee, Ji Won Lee, Sung Eun Jung, Jae Hee Chung, Yun-Mee Choe, Tae Gil Heo, In Geol Ho, Hyun-Young Kim
    Cancer Research and Treatment.2020; 52(1): 117.     CrossRef
  • Health behaviors of caregivers of childhood cancer survivors: a cross-sectional study
    In Young Cho, Nack-Gyun Chung, Hee Jo Baek, Ji Won Lee, Ki Woong Sung, Dong Wook Shin, Jung Eun Yoo, Yun-Mi Song
    BMC Cancer.2020;[Epub]     CrossRef
  • Global trends in incidence rates of childhood liver cancers: A systematic review and meta‐analysis
    Paramita Dasgupta, Chloe Henshaw, Danny R. Youlden, Joanne F. Aitken, Ashleigh Sullivan, Helen Irving, Peter D. Baade
    Paediatric and Perinatal Epidemiology.2020; 34(5): 609.     CrossRef
  • Immunotherapy in Pediatric Solid Tumors
    Jung Yoon Choi
    Clinical Pediatric Hematology-Oncology.2020; 27(1): 22.     CrossRef
  • Pediatric Palliative Care
    Min Sun Kim
    Clinical Pediatric Hematology-Oncology.2020; 27(1): 55.     CrossRef
  • The Financial Burden Associated with Medical Costs among Childhood Cancer Patients and Their Families Related to Their Socioeconomic Status: The Perspective of National Health Insurance Service
    Wonjeong Chae, Juyeong Kim, Sohee Park, Eun-Cheol Park, Sung-In Jang
    International Journal of Environmental Research and Public Health.2020; 17(17): 6020.     CrossRef
  • Aerobic training versus strength exercises on muscle strength and quality of life for children with acute lymphoblastic leukemia
    Doaa Mohamed, Faten Abd Alazim, Elham Salem, Nesreen Ali, Dina Elgalaly
    Bulletin of Faculty of Physical Therapy.2020;[Epub]     CrossRef
  • Symptom clusters in childhood cancer survivors in Korea: A latent class analysis
    Hye Chong Hong, Young Man Kim, Ari Min
    European Journal of Cancer Care.2020;[Epub]     CrossRef
  • Survival and long-term toxicities of pediatric Hodgkin lymphoma after combined modality treatment: a single institute experience
    Kye Jin Song, Jin-hong Park, Ho Joon Im, Seung Do Ahn
    Radiation Oncology Journal.2020; 38(3): 198.     CrossRef
  • Looking into the life of technology-dependent children and their caregivers in Korea: lifting the burden of too many responsibilities
    Yu Hyeon Choi, Min Sun Kim, Cho Hee Kim, In Gyu Song, June Dong Park, Dong In Suh, Hyung-Ik Shin
    BMC Pediatrics.2020;[Epub]     CrossRef
  • Minimal Residual Disease Detection in Pediatric Acute Lymphoblastic Leukemia
    Miyoung Kim, Chan-Jeoung Park
    Clinical Pediatric Hematology-Oncology.2020; 27(2): 87.     CrossRef
  • Childhood cancer epidemiology in the Czech Republic (1994–2016)
    Denisa Krejci, Michaela Zapletalova, Ivana Svobodova, Viera Bajciova, Peter Mudry, Vratislav Smelhaus, Jaroslav Sterba, Jan Stary, Riccardo Capocaccia, Ladislav Dusek
    Cancer Epidemiology.2020; 69: 101848.     CrossRef
  • Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia
    Hyery Kim
    Clinical Pediatric Hematology-Oncology.2019; 26(1): 12.     CrossRef
  • Clinical ascertainment of health outcomes in Asian survivors of childhood cancer: a systematic review
    Long Hin Jonathan Poon, Chun-Pong Yu, Liwen Peng, Celeste Lom-Ying Ewig, Hui Zhang, Chi-Kong Li, Yin Ting Cheung
    Journal of Cancer Survivorship.2019; 13(3): 374.     CrossRef
  • Ewing Sarcoma
    Hee Young Ju
    Clinical Pediatric Hematology-Oncology.2019; 26(1): 27.     CrossRef
  • Temporal trends in incidence of childhood cancer in Switzerland, 1985–2014
    Grit Sommer, Matthias Schindler, Shelagh Redmond, Verena Pfeiffer, Garyfallos Konstantinoudis, Roland A. Ammann, Marc Ansari, Heinz Hengartner, Gisela Michel, Claudia E. Kuehni
    Cancer Epidemiology.2019; 61: 157.     CrossRef
  • Influenza vaccination in caregivers of childhood cancer survivors
    In Young Cho, Jung Eun Yoo, Hyeonyoung Ko, Dong Wook Shin, Ji Won Lee, Hee Jo Baek, Nack-Gyun Chung, Ki Woong Sung, Yun-Mi Song
    Journal of Cancer Survivorship.2019; 13(6): 993.     CrossRef
  • Worldwide Trends in Survival From Common Childhood Brain Tumors: A Systematic Review
    Fabio Girardi, Claudia Allemani, Michel P. Coleman
    Journal of Global Oncology.2019; (5): 1.     CrossRef
  • Implementing Yogyakarta Pediatric Cancer Registry for 16 years
    Sri Mulatsih, Adnina Hariningrum, Ignatius Purwanto, Rizki Oktasari
    Paediatrica Indonesiana.2019; 59(4): 188.     CrossRef
  • Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia
    Tae Yang Song, Sang Hoon Lee, Gun Kim, Hee Jo Baek, Tai Ju Hwang, Hoon Kook
    Blood Research.2018; 53(1): 25.     CrossRef
  • School performance of childhood cancer survivors in Korea: A multi‐institutional study on behalf of the Korean Society of Pediatric Hematology and Oncology
    Meerim Park, Hyeon Jin Park, Jae Min Lee, Hee Young Ju, Byung Kiu Park, Eun‐Seung Yu, Hyung‐Kook Yang, Ji Yoon Kim, Sang Kyu Park, Young Ho Lee, Ye Jee Shim, Heung Sik Kim, Jun Ah Lee, Yeon‐Jung Lim, Hee Won Cheuh, Ji Kyoung Park, Mee Jeong Lee, Soon Ki K
    Psycho-Oncology.2018; 27(9): 2257.     CrossRef
  • Second malignant neoplasms after childhood cancer: A nationwide population-based study in Korea
    Hee Young Ju, Eun-Kyeong Moon, Jiwon Lim, Byung Kiu Park, Hee Young Shin, Young-Joo Won, Hyeon Jin Park, Samir M. Dalia
    PLOS ONE.2018; 13(11): e0207243.     CrossRef
  • Treatment outcome of pediatric acute lymphoblastic leukemia in Yeungnam region: Multicenter retrospective study of Study Alliance of Yeungnam Pediatric Hematology-Oncology (SAYPH)
    Eu Jeen Yang, Kyung Mi Park, Jae Min Lee, Jeong Ok Hah, Sang Kyu Park, Jin Kyung Suh, Ji Yoon Kim, Kun Soo Lee, Jikyoung Park, Eun Sil Park, Jaeyoung Lim, Ye Jee Shim, Heung Sik Kim, Seom Gim Kong, Heewon Chueh, Eun Jin Choi, Jeong A Park, Young Tak Lim
    Pediatric Hematology and Oncology.2018; 35(4): 276.     CrossRef
  • Neuroblastoma causes alterations of the intestinal microbiome, gut hormones, inflammatory cytokines, and bile acid composition
    Christoph Castellani, Georg Singer, Margarita Kaiser, Thomas Kaiser, Jianfeng Huang, Daniela Sperl, Karl Kashofer, Guenter Fauler, Barbara Guertl‐Lackner, Gerald Höfler, Holger Till
    Pediatric Blood & Cancer.2017;[Epub]     CrossRef
  • Childhood, adolescent and young adult cancer incidence in Japan in 2009–2011
    Kota Katanoda, Akiko Shibata, Tomohiro Matsuda, Megumi Hori, Kayo Nakata, Yoshitaka Narita, Chitose Ogawa, Wataru Munakata, Akira Kawai, Hiroshi Nishimoto
    Japanese Journal of Clinical Oncology.2017; 47(8): 762.     CrossRef
  • Prognostic factors and treatment of pediatric acute lymphoblastic leukemia
    Jae Wook Lee, Bin Cho
    Korean Journal of Pediatrics.2017; 60(5): 129.     CrossRef
  • Metabolic syndrome induced by anticancer treatment in childhood cancer survivors
    Hee Won Chueh, Jae Ho Yoo
    Annals of Pediatric Endocrinology & Metabolism.2017; 22(2): 82.     CrossRef
  • Awareness about past diagnosis and treatment history: nationwide survey of childhood cancer survivors and their parents
    Eunmi Ahn, Hyeon Jin Park, Hee Jo Baek, Pyoung Han Hwang, Young Ho Lee, Byung-Kiu Park, Young So Kim, Hye-Young Shim, Dongwook Shin, Hyung Kook Yang, Jong Hyock Park, Kyung Duk Park
    Japanese Journal of Clinical Oncology.2017; 47(10): 962.     CrossRef
  • A Systematic Review of Interventions with Siblings of Pediatric Cancer Patients
    Soo-yeon Han, Ji-Hye Hwang, Cho-hee Kim, Hye-young Jang, Kyung-Sook Bang
    Child Health Nursing Research.2017; 23(3): 394.     CrossRef
  • Gonadal and Sexual Dysfunction in Childhood Cancer Survivors
    Ju Young Yoon, Hyeon Jin Park, Hee Young Ju, Jong Hyung Yoon, Jin Soo Chung, Sang Hyun Hwang, Dong Ock Lee, Hye Young Shim, Byung-Kiu Park
    Cancer Research and Treatment.2017; 49(4): 1057.     CrossRef
  • A multicenter study of malignant oral and maxillofacial lesions in children and adolescents
    José Alcides Almeida de Arruda, Leni Verônica de Oliveira Silva, Camila de Nazaré Alves de Oliveira Kato, Lauren Frenzel Schuch, Aline Carvalho Batista, Nádia Lago Costa, Sandra Beatriz Chaves Tarquinio, Elena Riet Correa Rivero, Vinícius Coelho Carrard,
    Oral Oncology.2017; 75: 39.     CrossRef
  • Seasonal trends of diagnosis of childhood malignant diseases and viral prevalence in South Korea
    Kyu Seok Shim, Min Hyung Kim, Choong Nam Shim, Minkyu Han, In Seok Lim, Soo Ahn Chae, Sin Weon Yun, Na Mi Lee, Dae Yong Yi, Hyery Kim
    Cancer Epidemiology.2017; 51: 118.     CrossRef
  • 16,168 View
  • 430 Download
  • 59 Web of Science
  • 67 Crossref
Close layer
Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience
Che Ry Hong, Hyoung Jin Kang, Hee Young Ju, Ji Won Lee, Hyery Kim, Sung-Hye Park, Il Han Kim, Kyung Duk Park, Hee Young Shin
Cancer Res Treat. 2015;47(4):889-896.   Published online January 2, 2015
DOI: https://doi.org/10.4143/crt.2013.176
AbstractAbstract PDFPubReaderePub
Purpose
Malignant rhabdoid tumor (MRT) is a rare and highly aggressive tumor that affects young children. Due to its extreme rarity, most of the available data are based on retrospective case series. To add to the current knowledge of this disease, we reviewed the patients treated for extra-cranial MRT in our institute. Materials and Methods A retrospective medical record review was conducted on children treated for pathologically confirmed extra-cranial MRT at Seoul National University Children’s Hospital between January 2003 and May 2013. Results Eleven patients (7 boys, 4 girls) were diagnosed with extra-cranial MRT at a median age of 9 months old. INI1 staining was important in the pathological confirmation. Six patients (55%) had renal MRT and five (45%) had soft tissue MRT. Five patients (45%) had metastases at diagnosis. All patients underwent chemotherapy, eight patients (73%) underwent surgery, six patients (55%) received therapeutic radiotherapy, and four patients (36%) underwent high dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) with melphalan, etoposide, and carboplatin. Five patients (45%) died of disease following progression (n=3) or relapse (n=2), however, there was no treatment related mortality. The overall survival of the cohort was 53.0% and the event-free survival was 54.5% with a median follow-up duration of 17.8 months (range, 2.3 to 112.3 months). Conclusion Extra-cranial MRT is still a highly aggressive tumor in young children. However, the improved survival of our cohort is promising and HDCT/ASCR with melphalan, etoposide, and carboplatin may be a promising treatment option.

Citations

Citations to this article as recorded by  
  • A Review of Wilms Tumor
    Valeria Smith, Andrew Wahba, Murali Chintagumpala, Priya Mahajan
    Pediatrics in Review.2025; 46(4): 206.     CrossRef
  • Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach
    Siqi Xie, Yuanyuan Fang, Yingying Yang, Lan Liu, Jianxi Bai, Sheng Lin, Bing Zhang, Yifan Fang
    European Journal of Pediatrics.2023; 183(2): 557.     CrossRef
  • Infantile Extracranial Rhabdoid Tumor of the Scalp
    Sura Al Rawabdeh, Deifallah Alsharari, Hayat Khasawneh, Ola M. Al Waqfi, Qamar Yaser Malabeh, Hiathem Abu Alhaija, Raed Mohammad Aljubour, Hamzeh M. Alkhawaldeh, Pablo Fernandez Pe as
    Case Reports in Medicine.2021; 2021: 1.     CrossRef
  • Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing
    Che Ry Hong, Hyoung Jin Kang, Seol Ju Moon, Jaeseong Oh, Kyung Taek Hong, Jung Yoon Choi, Kyung-Sang Yu, Hee Young Shin
    Bone Marrow Transplantation.2020; 55(1): 137.     CrossRef
  • Successful Treatment of Extra‐Renal Noncerebral Rhabdoid Tumors with VIDE
    Naoko Yasui, Akihiko Yoshida, Eisuke Kobayashi, Fumihiko Nakatani, Hiroshi Kawamoto
    Pediatric Blood & Cancer.2016; 63(2): 352.     CrossRef
  • 14,899 View
  • 150 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents
Hyery Kim, Eun Sil Park, Soo Hyun Lee, Hong Hoe Koo, Hyo Sun Kim, Chuhl Joo Lyu, So Eun Jun, Young Tak Lim, Hee Jo Baek, Hoon Kook, Ji Won Lee, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyeo Seop Ahn
Cancer Res Treat. 2014;46(4):358-365.   Published online July 21, 2014
DOI: https://doi.org/10.4143/crt.2013.047
AbstractAbstract PDFPubReaderePub
Purpose
Despite the rapid improvement in survival rate from Burkitt lymphoma and mature B-cell lymphoblastic leukemia (B-ALL) in children, a small subset of patients do not respond to first-line chemotherapy or experience relapse (RL). Herein, we report the clinical characteristics and outcomes of these patients.
Materials and Methods
RL or refractory Burkitt lymphoma and mature B-ALL in 125 patients diagnosed from 1990 to 2009 were retrospectively analyzed.
Results
Nineteen patients experienced RL or progressive disease (PD). Among them, 12 patients had PD or RL less than six months after initial treatment and seven had late RL. Seven patients achieved complete response (CR), 11 had PD, and one had no more therapy. Six patients who achieved CR survived without evidence of disease and four of them underwent high-dose chemotherapy (HDC) followed by stem cell transplantation (SCT). However, 11 patients who failed to obtain CR eventually died of their disease. Five-year overall survival (OS) was 31.6±10.7%. OS of patients with late RL was superior to that of patients with early RL (57.1±18.7%, vs. 16.7±10.8%, p=0.014). Achievement of CR after reinduction had significant OS (p < 0.001). OS for patients who were transplanted was superior (p < 0.01). In multivariate analysis, achievement of CR after reinduction chemotherapy showed an association with improved OS (p=0.05).
Conclusion
Late RL and chemotherapy-sensitive patients have the chance to achieve continuous CR using HDC/SCT, whereas patients who are refractory to retrieval therapy have poor prognosis. Therefore, novel salvage strategy is required for improvement of survival for this small set of patients.

Citations

Citations to this article as recorded by  
  • Comprehensive analysis of relapsed‐refractory mature B‐cell non‐Hodgkin lymphoma in children and adolescents
    Sara Mato, Lorenzo Carità, Ariadna Colmenero, Mara Andrés, Olga Balagué, Maitane Andión, Itziar Astigarraga, Verónica Celis, Carmen Mendoza, Pilar Guerra‐García, Lorena Valero, Ana Galera, María Tallón, Melina Pol, Natalia Castrejón‐de‐Anta, Leonie Frauen
    British Journal of Haematology.2025;[Epub]     CrossRef
  • The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation
    T. T. Valiev, A. A. Khachatryan, S. V. Goryacheva, N. A. Batmanova, K. I. Kirgizov, S. R. Varfolomeeva
    Oncohematology.2024; 19(1): 40.     CrossRef
  • Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies
    Francesco Malfona, Anna Maria Testi, Sabina Chiaretti, Maria Luisa Moleti
    Blood and Lymphatic Cancer: Targets and Therapy.2024; Volume 14: 1.     CrossRef
  • MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptation
    Rosa Bordone, Devon Michael Ivy, Rodrigo D’Amico, Martina Barba, Miriam Gaggianesi, Fiorella Di Pastena, Bianca Cesaro, Francesca Bufalieri, Alessio Balzerano, Enrico De Smaele, Giuseppe Giannini, Lucia Di Marcotullio, Alessandro Fatica, Giorgio Stassi, L
    Oncogene.2024; 43(46): 3349.     CrossRef
  • Prognostic Factors and Treatment Outcome of Relapsing and Refractory Pediatric Mature B-cell Non-Hodgkin Lymphoma, Children’s Cancer Hospital Egypt Experience
    Samah F. Semary, Hany Abdel Rahman, Naglaa Elkinaai, Iman Zaky, Nouran Nagy, Sherine Salem, Asmaa Hamoda
    Journal of Pediatric Hematology/Oncology.2023; 45(6): e757.     CrossRef
  • Chronic Recurrent Multifocal Osteomyelitis Associated With Inflammatory Bowel Disease Successfully Treated With Infliximab
    Shinhyeung Kwak, Dongsub Kim, Joon-sik Choi, Yoonsun Yoon, Eun Sil Kim, Mi Jin Kim, So-Young Yoo, Jong Sup Shim, Yon Ho Choe, Yae-Jean Kim
    Pediatric Infection & Vaccine.2022; 29(2): 96.     CrossRef
  • Burkitt lymphoma
    Cristina López, Birgit Burkhardt, John K. C. Chan, Lorenzo Leoncini, Sam M. Mbulaiteye, Martin D. Ogwang, Jackson Orem, Rosemary Rochford, Mark Roschewski, Reiner Siebert
    Nature Reviews Disease Primers.2022;[Epub]     CrossRef
  • Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
    Xueqian Li, Meng Zhou, Jiaqian Qi, Yue Han
    Clinical Lymphoma Myeloma and Leukemia.2021; 21(3): e227.     CrossRef
  • Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
    Birgit Burkhardt, Mary Taj, Nathalie Garnier, Veronique Minard-Colin, Volkan Hazar, Karin Mellgren, Tomoo Osumi, Alina Fedorova, Natalia Myakova, Jaime Verdu-Amoros, Mara Andres, Edita Kabickova, Andishe Attarbaschi, Alan Kwok Shing Chiang, Eva Bubanska,
    Cancers.2021; 13(9): 2075.     CrossRef
  • Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells
    Ghazaleh Khalili-Tanha, Meysam Moghbeli
    Cellular & Molecular Biology Letters.2021;[Epub]     CrossRef
  • EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins
    Leah Fitzsimmons, Rachel Cartlidge, Catherine Chang, Nenad Sejic, Laura C. A. Galbraith, Chathura D. Suraweera, Deborah Croom-Carter, Grant Dewson, Rosemary J. Tierney, Andrew I. Bell, Clare Shannon-Lowe, Marco J. Herold, Alan B. Rickinson, Peter M. Colma
    Cell Death & Differentiation.2020; 27(5): 1554.     CrossRef
  • Treatment of relapsed/refractory paediatric aggressive B‐cell non‐Hodgkin lymphoma
    Maria L. Moleti, Anna M. Testi, Robin Foà
    British Journal of Haematology.2020; 189(5): 826.     CrossRef
  • Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia
    Jin Kyung Suh, Yi-Jin Gao, Jing-Yan Tang, Shiann-Tarng Jou, Dong-Tsamn Lin, Yoshiyuki Takahashi, Seiji Kojima, Ling Jin, Yonghong Zhang, Jong Jin Seo
    Cancer Research and Treatment.2020; 52(2): 359.     CrossRef
  • An 8-year retrospective study of adult and paediatric Burkitt’s lymphoma at Tygerberg Hospital, South Africa
    Ernest Musekwa, Zivanai C. Chapanduka, Fatima Bassa, Mariana Kruger
    South African Journal of Oncology.2020;[Epub]     CrossRef
  • Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4
    Zijun Zhen, Jia Zhu, Juan Wang, Suying Lu, Feifei Sun, Junting Huang, Xiaofei Sun
    Pediatric Hematology and Oncology.2020; 37(6): 489.     CrossRef
  • Knockdown of lncRNA MCM3AP-AS1 Attenuates Chemoresistance of Burkitt Lymphoma to Doxorubicin Treatment via Targeting the miR-15a/EIF4E Axis


    Chao Guo, Ming Gong, Zhenling Li
    Cancer Management and Research.2020; Volume 12: 5845.     CrossRef
  • Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
    Kimberly Davies, Matthew Barth, Saro Armenian, Anthony N. Audino, Phillip Barnette, Branko Cuglievan, Hilda Ding, James B. Ford, Paul J. Galardy, Rebecca Gardner, Rabi Hanna, Robert Hayashi, Alexandra E. Kovach, Andrea Judit Machnitz, Kelly W. Maloney, Li
    Journal of the National Comprehensive Cancer Network.2020; 18(8): 1105.     CrossRef
  • Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma
    Naoto Fujita, Ryoji Kobayashi, Yoshiko Atsuta, Fuminori Iwasaki, Junji Suzumiya, Yoji Sasahara, Masami Inoue, Katsuyoshi Koh, Tsukasa Hori, Hiroaki Goto, Tatsuo Ichinohe, Yoshiko Hashii, Koji Kato, Ritsuro Suzuki, Tetsuo Mitsui
    International Journal of Hematology.2019; 109(4): 483.     CrossRef
  • An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence
    Kevin Kalisz, Francesco Alessandrino, Rose Beck, Daniel Smith, Elias Kikano, Nikhil H. Ramaiya, Sree Harsha Tirumani
    Insights into Imaging.2019;[Epub]     CrossRef
  • Unusual lymphoid malignancy and treatment response in two children with Down syndrome
    Ashley Geerlinks, Jennifer Keis, Bo Ngan, Amer Shammas, Reza Vali, Johann Hitzler
    Pediatric Blood & Cancer.2019;[Epub]     CrossRef
  • Outcome of relapse in children and adolescents with B‐cell non‐Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study
    Charlotte Rigaud, Anne Auperin, Anne Jourdain, Stephanie Haouy, Marie‐Laure Couec, Nathalie Aladjidi, Virginie Gandemer, Anne Lambliotte, Geneviève Plat, Judith Landman‐Parker, Jean Michon, Thierry Leblanc, Catherine Patte, Veronique Minard‐Colin
    Pediatric Blood & Cancer.2019;[Epub]     CrossRef
  • Anti-Tumor Effect of a Novel DOX/GA-CdTe QD was Mediated by Apoptotic and Autophagic Cell Death
    Huaqin Zuo, Fan Wang, Di Zhou, Yi Zhou, Bing Chen, Jian Ouyang, Peipei Xu
    Nano.2017; 12(01): 1750011.     CrossRef
  • Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease
    Anna Kieslich, Peter Ruf, Horst Lindhofer, Raynold Buhmann, Angelika Eggert, Patrick Hundsdoerfer
    Leukemia & Lymphoma.2017; 58(8): 1989.     CrossRef
  • Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphoma
    Nicholas J. Short, Hagop M. Kantarjian, Heidi Ko, Joseph D. Khoury, Farhad Ravandi, Deborah A. Thomas, Guillermo Garcia‐Manero, Maria Khouri, Jorge E. Cortes, William G. Wierda, Srdan Verstovsek, Zeev Estrov, Alessandra Ferrajoli, Philip A. Thompson, Sher
    American Journal of Hematology.2017;[Epub]     CrossRef
  • 16,670 View
  • 199 Download
  • 24 Crossref
Close layer
Clinical Characteristics and Treatment Results of Pediatric Osteosarcoma: The Role of High Dose Chemotherapy with Autologous Stem Cell Transplantation
Ji Won Lee, Hyery Kim, Hyoung Jin Kang, Han-Soo Kim, Sung-Hye Park, In-One Kim, Hyo Seop Ahn, Hee Young Shin
Cancer Res Treat. 2008;40(4):172-177.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.172
AbstractAbstract PDFPubReaderePub
Purpose

In this study, we investigated the clinical characteristics and treatment results of osteosarcoma during the past 7 years, and evaluated the role of high dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT).

Materials and Methods

We retrospectively analyzed the clinical data of patients who were diagnosed as osteosarcoma at our center from January, 2000 to December, 2007.

Results

The 5-year overall survival and event-free survival of the patients were 72.6% and 55.9%, respectively. Seventeen (41.5%) patients showed disease progression during treatment or relapse after the end of treatment. The patients who had metastasis at diagnosis or who had a lower grade of necrosis after neoadjuvant chemotherapy showed decreased overall and event-free survival. Four patients received ASCT after HDCT, and 3 of them are alive without disease.

Conclusions

The patients who relapsed or had refractory osteosarcoma or who had metastasis at diagnosis or a lower grade of necrosis after neoadjuvant chemotherapy showed poor prognosis. HDCT with ASCT could be an alternative treatment option for these patients.

Citations

Citations to this article as recorded by  
  • High‐dose chemotherapy followed by autologous stem cell transplantation in pediatric patients with relapsed osteosarcoma
    Sung Han Kang, Wanlim Kim, Jong Seok Lee, Jin Kyung Suh, Hyery Kim, Dong Kwan Kim, Se Hoon Choi, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Sung Wook Seo, Ho Joon Im, Ji Won Lee, Kyung‐Nam Koh
    Pediatric Blood & Cancer.2023;[Epub]     CrossRef
  • Favorable outcome of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with nonmetastatic osteosarcoma and low-degree necrosis
    Kyung Taek Hong, Hyun Jin Park, Bo Kyung Kim, Hong Yul An, Jung Yoon Choi, Jung-Eun Cheon, Sung-Hye Park, Han-Soo Kim, Hyoung Jin Kang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The Outcome of Children With Malignant Bone Tumors: A Single-Center Experience
    Mohammadreza Bordbar, Ali Sarfaraz, Sezaneh Haghpanah, Omidreza Zekavat, Soheila Zareifar, Tahereh Zarei
    Global Pediatric Health.2021;[Epub]     CrossRef
  • 1
    L.V. Hryvkova
    Practical oncology.2021; 4(1): 30.     CrossRef
  • Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma
    Suguru Uemura, Takeshi Mori, Shinya Ishiko, Satoru Takafuji, Nanako Nino, Nobuyuki Yamamoto, Akira Hayakawa, Noriyuki Nishimura, Hitomi Hara, Teruya Kawamoto, Toshihiro Akisue, Kazumoto Iijima
    Pediatric Hematology and Oncology.2020; 37(4): 337.     CrossRef
  • Pulmonary tuberculosis mimicking radiation pneumonitis in a patient with neck malignancy
    Kyungsoo Bae, Kyung Nyeo Jeon, Hoon Sik Choi, Dae Hyun Song, Ho Cheol Kim
    Medicine.2019; 98(27): e16398.     CrossRef
  • High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma
    C R Hong, H J Kang, M S Kim, H Y Ju, J W Lee, H Kim, H-S Kim, S-H Park, K D Park, J D Park, H Y Shin, H S Ahn
    Bone Marrow Transplantation.2015; 50(10): 1375.     CrossRef
  • High‐dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study
    Kjetil Boye, Adalberto Brach Del Prever, Mikael Eriksson, Gunnar Sæter, Amelia Tienghi, Paula Lindholm, Franca Fagioli, Sigmund Skjeldal, Stefano Ferrari, Kirsten Sundby Hall
    Pediatric Blood & Cancer.2014; 61(5): 840.     CrossRef
  • LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy
    XIN HUA LONG, ZHEN HAO ZHONG, AI FEN PENG, LIANG BO ZHU, HENG WANG, GUO MEI ZHANG, ZHI LI LIU
    Molecular Medicine Reports.2014; 10(6): 2967.     CrossRef
  • Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma
    Colin Moore, Don Eslin, Alejandro Levy, Jessica Roberson, Vincent Giusti, Robert Sutphin
    Pediatric Blood & Cancer.2010; 55(6): 1096.     CrossRef
  • Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma
    Masanori Kawano, Hideji Nishida, Yasunari Nakamoto, Hiroshi Tsumura, Hiroyuki Tsuchiya
    Clinical Orthopaedics and Related Research®.2010; 468(5): 1373.     CrossRef
  • 10,456 View
  • 67 Download
  • 11 Crossref
Close layer
Clinical Results of Chemotherapy based Treatment in Retinoblastoma Patients: A Single Center Experience
Hyery Kim, Ji Won Lee, Hyoung Jin Kang, Hyeon Jin Park, Yoon Yi Kim, Hee Young Shin, Young Suk Yu, Il Han Kim, Hyo Seop Ahn
Cancer Res Treat. 2008;40(4):164-171.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.164
AbstractAbstract PDFPubReaderePub
Purpose

Retinoblastoma is the most common intraocular malignancy in children. Since the 1990s, chemotherapy was indicated for intraocluar disease to reduce the frequency of enucleation and spare the complications associated with external beam radiation. In this study, we analyzed treatment results of retinoblastoma in our institute.

Materials and Methods

Datas from children diagnosed with retinoblastoma and treated at Seoul National University Children's Hospital between 1986 and 2008 were analyzed retrospectively. We utilized cyclophosphamide, vincristine, adriamycin, and methotrexate (CVAM) for OPD-based adjuvant chemotherapy. From 1990, primary chemotherapy was administered to patients with intraocular disease for eyeball-saving and patients received a combination of etoposide, vincristine, cisplatin (or ifosfamide) as a moderately intensive regimen, or a combination of cisplatin, doxorubicin, etoposide, and cycophosphamide (CDEC) as a highly intensive regimen.

Results

One hundred eighteen children were analyzed. There were 68 unilateral and 50 bilateral diseases. The median age at diagnosis was 1 year and Reese-Ellsworth stage V was the most common stage at the time of diagnosis. All patients were treated by chemotherapy-based multimodality methods, and primary chemotherapy was administered to 80 patients. The 10-year overall and event-free survival rate of all patients were 93.9% and 91.6%, respectively. Two patients who died were in the CDEC regimen group, but there was no significant statistical difference in survival rates by chemotherapy regimens. Fifty-six of 114 eyeballs were saved after primary chemotherapy-based treatment, and the eyeball-saving rate was 49.1%. Six patients relapsed after enucleation and 2 patients were treated successfully after autologous PBSCT. Osteosarcoma occurred in 2 patients as a secondary malignancy, and facial asymmetry after radiotherapy was the most common long-term sequelae.

Conclusions

In this study, the overall and event-free survival rates of retinoblastoma were satisfactory and eye-saving was possible with primary chemotherapy. Development of new chemotherapeutic regimens and a team approach are necessary to improve the eyeball-saving rate.

Citations

Citations to this article as recorded by  
  • The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases
    Chiara Crotti, Nicola Ughi, Emanuela Beretta, Antonio Luca Brucato, Greta Carrara, Maria Sole Chimenti, Paola Conigliaro, Francesca Crisafulli, Giovanna Cuomo, Emma Di Poi, Khadija El Auofy, Micaela Fredi, Maria Chiara Gerardi, Maria Gerosa, Ariela Hoxa,
    Reumatismo.2025;[Epub]     CrossRef
  • The Efficacy of Alternate Systemic Intravenous Chemotherapy and Intra-arterial Chemotherapy Approach for Eye Globe Salvage in Retinoblastoma
    Jung Woo Han, Christopher Seungkyu Lee, Seung Min Hahn, Won Kee Ahn, Hyo Sun Kim, Hyeseon Yun, Sung Chul Lee, Byung Moon Kim, Dong Joon Kim, Chuhl Joo Lyu
    Cancer Research and Treatment.2023; 55(1): 270.     CrossRef
  • Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors
    Emily S Wong, Richard W Choy, Yuzhou Zhang, Wai Kit Chu, Li Jia Chen, Chi Pui Pang, Jason C Yam
    The Lancet Global Health.2022; 10(3): e380.     CrossRef
  • Twenty-Year Retrospective Study of Post-Enucleation Chemotherapy in High-Risk Patients with Unilateral Retinoblastoma
    Yoon Sunwoo, Jung Yoon Choi, Hyun Jin Park, Bo Kyung Kim, Kyung Taek Hong, Sang In Khwarg, Jaemoon Koh, Sung-Hye Park, Dong Hyun Jo, Jeong Hun Kim, Jung-Eun Cheon, Hyoung Jin Kang
    Children.2022; 9(12): 1983.     CrossRef
  • Development of New Solitary Retinoblastoma Tumors during and after Chemotherapy
    Won Jong Choi, Dong Hyun Jo, Hyoung Jin Kang, Hee Young Shin, Young Suk Yu, Jeong Hun Kim
    Korean Journal of Ophthalmology.2021; 35(1): 73.     CrossRef
  • Outcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center study
    Jassada Buaboonnam, Nattee Narkbunnam, Nassawee Vathana, Chayamon Takpradit, Kamon Phuakpet, Bunchoo Pongtanakul, Sasima Tongsai, La-Ongsri Atchaneeyasakul, Kleebsabai Sanpakit
    Pediatric Hematology and Oncology.2019; 36(2): 73.     CrossRef
  • Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
    Francis L. Munier, Maja Beck-Popovic, Guillermo L. Chantada, David Cobrinik, Tero T. Kivelä, Dietmar Lohmann, Philippe Maeder, Annette C. Moll, Angel Montero Carcaboso, Alexandre Moulin, Paula Schaiquevich, Ciara Bergin, Paul J. Dyson, Susan Houghton, Fra
    Progress in Retinal and Eye Research.2019; 73: 100764.     CrossRef
  • Outcomes of Proton Beam Radiation Therapy for Retinoblastoma With Vitreous Seeds
    Eun Hye Jung, Jeong Hun Kim, Joo Young Kim, Dong Hyun Jo, Young Suk Yu
    Journal of Pediatric Hematology/Oncology.2018; 40(8): 569.     CrossRef
  • Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress
    Zeren Shen, Jinjin Shao, Jiabin Dai, Yuchen Lin, Xiaochun Yang, Jian Ma, Qiaojun He, Bo Yang, Ke Yao, Peihua Luo
    Toxicology Reports.2016; 3: 78.     CrossRef
  • Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma
    Seung Min Hahn, Hyo Sun Kim, Dong Joon Kim, Sung Chul Lee, Chuhl Joo Lyu, Jung Woo Han
    Pediatric Hematology and Oncology.2016; 33(1): 74.     CrossRef
  • Diagnosis & Treatment of Retinoblastoma: Current Review
    Heewon Chueh
    Clinical Pediatric Hematology-Oncology.2015; 22(1): 38.     CrossRef
  • High‐dose chemotherapy with autologous stem cell rescue for treatment of retinoblastoma: Report of five cases
    Désirée Caselli, Angela Tamburini, Agostino La Torre, Liliana Pollazzi, Veronica Tintori, Franco Bambi, Roberto Caputo, Maurizio Aricò
    Pediatric Transplantation.2014; 18(6): 631.     CrossRef
  • Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments
    Carlo Venturi, Sandra Bracco, Alfonso Cerase, Samuele Cioni, Paolo Galluzzi, Paola Gennari, Ignazio M. Vallone, Rebecca Tinturini, Cesare Vittori, Sonia De Francesco, Mauro Caini, Alfonso D’Ambrosio, Paolo Toti, Alessandra Renieri, Theodora Hadjistilianou
    Acta Ophthalmologica.2013; 91(4): 335.     CrossRef
  • Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma
    Aman Khurana, Christina A. Eisenhut, Wenshuai Wan, Katayoon B. Ebrahimi, Chirag Patel, Joan M. O’Brien, Kristen Yeom, Heike E. Daldrup-Link
    European Radiology.2013; 23(5): 1271.     CrossRef
  • Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells
    HYUN BEOM SONG, HYOUNG-OH JUN, JIN HYOUNG KIM, YOUNG SUK YU, KYU-WON KIM, BON HONG MIN, JEONG HUN KIM
    Oncology Reports.2013; 30(6): 2713.     CrossRef
  • Combined Treatment with an Oncolytic Adenovirus and Antitumor Activity of Vincristine against Retinoblastoma Cells
    Xin Song, Haibo Wang, Renbing Jia, Biyun Cun, Xiaoping Zhao, Yixiong Zhou, Xiaofang Xu, Guanxiang Qian, Shengfang Ge, Xianqun Fan
    International Journal of Molecular Sciences.2012; 13(9): 10736.     CrossRef
  • Long Term Follow-up Results of External Beam Radiotherapy as Primary Treatment for Retinoblastoma
    Sang Yul Choi, Mi-Sook Kim, SungYul Yoo, ChulKoo Cho, YoungHoon Ji, KumBae Kim, YoungSeok Seo, Kyung Duk Park, JunAh Lee, Tai-Won Lee
    Journal of Korean Medical Science.2010; 25(4): 546.     CrossRef
  • 12,171 View
  • 85 Download
  • 17 Crossref
Close layer
Initial Response to Treatment was Highly Associated with the Prognosis of Childhood Rhabdomyosarcoma: A Retrospective Analysis of a Single Center Experience in Korea
Jeong A Park, Eun Kyung Kim, Hyoung Jin Kang, Hee Young Shin, Il Han Kim, Hyo Seop Ahn
Cancer Res Treat. 2008;40(3):111-115.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.111
AbstractAbstract PDFPubReaderePub
Purpose

Following the introduction of a multimodal approach to diagnosis and treatment, the prognosis of rhabdomyosarcoma (RMS) has markedly improved over the last three decades. However, there are few data on treatment outcomes in Korean patients.

Materials and Methods

We performed a retrospective analysis of 77 patients with RMS diagnosed and treated at Seoul National University Children's Hospital between 1986 and 2005.

Results

The overall 5-year survival and event-free survival rates for all patients were 77% and 59%, respectively. The Intergroup Rhabdomyosarcoma Study clinical grouping and initial response to treatment (20-week response) were important prognostic factors.

Conclusions

The outcome of childhood RMS was closely associated with the initial staging and the initial response to treatment. Modulating therapies according to initial responses and risk factors is critical, and new treatment strategies for high-risk patients are needed.

Citations

Citations to this article as recorded by  
  • Adherence to Treatment, Response and Patterns of Failure in Pediatric Parameningeal Rhabdomyosarcoma: Experience From a Tertiary Cancer Care Center From India
    Soumyajit Roy, Sushmita Pathy, Bidhu K. Mohanti, Subhash Chander, Ahitagni Biswas
    Journal of Pediatric Hematology/Oncology.2017; 39(2): e62.     CrossRef
  • Pediatric rhabdomyosarcoma in India: A single-center experience
    Deepak Bansal, Anirban Das, Amita Trehan, Rakesh Kapoor, Naresh K. Panda, Radhika Srinivasan, Nandita Kakkar, Kushaljit S. Sodhi, Akshay K. Saxena, Katragadda Lakshmi Narasimha Rao
    Indian Pediatrics.2017; 54(9): 735.     CrossRef
  • The impact of radiotherapy on clinical outcomes in parameningeal rhabdomyosarcoma
    Yunseon Choi, Do Hoon Lim
    Radiation Oncology Journal.2016; 34(4): 290.     CrossRef
  • Rhabdomyosarcoma Treatment and Outcome at a Multidisciplinary Pediatric Cancer Center in Lebanon
    Maysaa Salman, Hani Tamim, Fouad Medlej, Tarek El-Ariss, Fatima Saad, Fouad Boulos, Toufic Eid, Samar Muwakkit, Nabil Khoury, Miguel Abboud, Raya Saab
    Pediatric Hematology and Oncology.2012; 29(4): 322.     CrossRef
  • Solid tumours of childhood
    Bruce O. Okoye
    Surgery (Oxford).2010; 28(8): 382.     CrossRef
  • Primary meningeal rhabdomyosarcoma associated with chronic subdural effusion
    Ji Yeoun Lee, Bo Sung Kim, Ji Hoon Phi, Hyoung Jin Kang, Sung-Hye Park, Kyu-Chang Wang, Il Han Kim, Byung-Kyu Cho, Seung-Ki Kim
    Journal of Neurosurgery: Pediatrics.2010; 5(2): 167.     CrossRef
  • 10,369 View
  • 38 Download
  • 6 Crossref
Close layer
Case Report
Carboxypeptidase-G2 Rescue in a Patient with High Dose Methotrexate-induced Nephrotoxicity
Eun Sil Park, Kyung Hee Han, Hyoung Soo Choi, Hee Young Shin, Hyo Seop Ahn
Cancer Res Treat. 2005;37(2):133-135.   Published online April 30, 2005
DOI: https://doi.org/10.4143/crt.2005.37.2.133
AbstractAbstract PDFPubReaderePub

A 13 year-old girl with osteosarcoma and pulmonary tumor recurrence developed acute renal failure following high dose methotrexate (12 g/m2) therapy, she had previously tolerated high dose methotrexate and her renal and hepatic functions were normal. Briefly, 48 hours after beginning methotrexate infusion her methotrexate concentration and creatinine level were 1338.8 µM/L and 5.8 mg/dl, respectively. Grade IV oral mucositis and neutropenia with fever developed at 144 hours after MTX infusion. Hydration and alkalinization were continued and leucovorin rescue was intensified based on the plasma MTX concentrations. Plasma exchange was performed twice and hemodialysis 3 times without problems, but methotraxate and creatinine levels remained high, 91.9 µM/L, and 2.5 mg/dl, respectively. After 3 courses of hemodialysis carboxypeptidase-G2 (CPDG2) was administered at 50 U/kg, intravenously over 5 minutes. After 15 minutes of CPDG2 (Voraxaze™) infusion, her plasma MTX concentration was 0.91 µM/L and no rebound elevation or side effects developed. Thirteen days post-MTX infusion her renal function had normalized. We report here our experience of a dramatic methotrexate level reduction caused by CPDG2 administration.

Citations

Citations to this article as recorded by  
  • Extracorporeal Treatment for Methotrexate Poisoning
    Marc Ghannoum, Darren M. Roberts, David S. Goldfarb, Jesper Heldrup, Kurt Anseeuw, Tais F. Galvao, Thomas D. Nolin, Robert S. Hoffman, Valery Lavergne, Paul Meyers, Sophie Gosselin, Tudor Botnaru, Karine Mardini, David M. Wood
    Clinical Journal of the American Society of Nephrology.2022; 17(4): 602.     CrossRef
  • Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients
    Jeffrey R. Scott, Yinmei Zhou, Cheng Cheng, Deborah A. Ward, Hope D. Swanson, Alejandro R. Molinelli, Clinton F. Stewart, Fariba Navid, Sima Jeha, Mary V. Relling, Kristine R. Crews
    Pediatric Blood & Cancer.2015; 62(9): 1518.     CrossRef
  • Resumption of high‐dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients
    Anthony M. Christensen, Jennifer L. Pauley, Alejandro R. Molinelli, John C. Panetta, Deborah A. Ward, Clinton F. Stewart, James M. Hoffman, Scott C. Howard, Ching‐Hon Pui, Alberto S. Pappo, Mary V. Relling, Kristine R. Crews
    Cancer.2012; 118(17): 4321.     CrossRef
  • 8,413 View
  • 62 Download
  • 3 Crossref
Close layer
Original Articles
Treatment Result of Pediatric Osteosarcoma with Intraarterial Cisplatin
Hyoung Soo Choi, Hyoung Jin Kang, Jun Ah Lee, Hyo Heong Han, Hyeon Jin Park, Eun Sun Yoo, Woo Sun Kim, Hee Young Shin, In One Kim, Sang Hoon Lee, Hyo Seop Ahn, Han Koo Lee
J Korean Cancer Assoc. 1998;30(1):169-177.
AbstractAbstract PDF
PURPOSE
This study was performed to determine the outcome after treatment of osteosarcoma with intraarterial cisplatin as a preoperative chematherapy regimen.
MATERIALS AND METHODS
Twenty five patients with extremity osteosarcoma were treated with intraarterial cisplatin at Seoul National University Children's Hospital from January 1987 to April 1996. The dose of cisplatin was 130 mg/m2 and three to six courses were repeated two- to three-week intervals, Systemic doxorubicin was added to six of these patients. This was followed by surgical resection(limb salvage or amputation) and postoperative adjuvant chemotherapy.
RESULTS
Limb-salvage was possible in twenty of these twenty five patients. Pulmonary metastasis was present in five patients at diagnosis and developed later in three patients. In six patients treated with systemic doxorubicin, pulmonary metastasis was absent at diagnosis and during follow-up period. Local recurrence after limb salvage was occurred in one patient and treated with amputation and systemic chemotherapy. Seven patients died from pulmonary metastssis and one from unknown cause. The follow-up duration of these patients was three to eighty eight months(median twenty two months) and the overall five-year survival and event free survival rate were 62.1% and 57.5%, respectively.
CONCLUSION
These data demonstrate that intraarterial cisplatin can be used as an effective regimen preoperatively for pediatric patients with extremity osteosarcoma. The combined use of systemic doxorubicin is expected to improve survival in patients with pulmonary metastasis.
  • 3,140 View
  • 15 Download
Close layer
A monoclonal antibody to CD 35 molecule-a monoclonal antibody to follicular dendritic cell in lymphoid tissues-
Sung Hee Park, Hee Young Shin, Joon Kim
J Korean Cancer Assoc. 1993;25(5):744-750.
AbstractAbstract PDF
No abstract available.
  • 2,050 View
  • 14 Download
Close layer
Experience of '8-drugs-in-a-day' chemotherapy for CNS primitive neuroectodermal tumor
Hee Young Shin, Hyo Sub Ahn
J Korean Cancer Assoc. 1993;25(5):707-716.
AbstractAbstract PDF
No abstract available.
  • 1,963 View
  • 12 Download
Close layer
Study on the treatment of childhood acute lymphoblastic leukemia
Sang Oh Na, Hee Young Shin, Hyo Seop Ahn, Sang Kyu Park
J Korean Cancer Assoc. 1992;24(3):390-400.
AbstractAbstract PDF
No abstract available.
  • 2,180 View
  • 14 Download
Close layer
Treatment of Childhood Acute Lymphoblastic Leukemia Diagnosed Jan . , 1978 Through Dec . , 1987 : Comparison between Standard - Risk and High - Risk Groups
Soon Ki Kim, Hee Young Shin, Hyo Seop Ahn
J Korean Cancer Assoc. 1990;22(3):539-549.
AbstractAbstract PDF
Of 328 children who were diagnosed as acute lymphoblastic leukemia at the Department of Pediatrics. Seoul National University Hospital from Jan., 1978 through Dec., 1987, 211 patients above one year af age were evaluable for induction chemotherapy. The leukemias were classified as standard risk (SR), comparison group (who had high-risk prognostic factors, but had been treated with standard regimen), or high- risk (HR) leukemia according to the prognostic criteria at diagnosis. Three regimens were compared and the results were as follows. 1) The complete remission (CR) rate was 97.1%(133/137), 81.0%(34/42) and 90.6%(29/32) in SR, comparison group. and HR group, respectively. And significant difference in the CR rate was seen between SR group and comparison group (p= 0.0001). 2) Of the patients remained in remission follow-up of each group showed 56.8% 5-yr disease-free survival (DFS)(+-5.9%, median follow-up 30 mo) in SR, 35.5% (+-9.1%, median 24 mo) in comparison group, and 76.0%(+- 8.5%, median 24 mo) in HR group. And significant difference in the 5yr-DFS rate were observed be(ween SR and comparison group (P = 0.007), between HR and comparison group (p = 0.002), respectively. 3) Induction failure was due to infection (n=2) bleeding (n=1) or uric acid nephropathy (n= 1) in SR drug resistance (n=3), infection (n=2), bleeding (n=2), or combind infection and bleeding (n=1) in comparison group, and bleeding (n=2) or infection (n= 1) in HR. Of the patients who were on maintenance chemotherapy in complete remission, 11 died due to infection: menigitis or meningoencephalitis (n=4), disseminated varicella (n=3), Pneumocystis carinii pneumonia (n=2), and sepsis (n=2). 4) In SR group, 29 patients experienced relapse: BM(n=18), CNS(n=3), BM and CNS(n=4), and testes (n=4). Two- third (n = 19) of them relapsed between 6mo to 2yr after initial remission. In comparison graup, 20 relapsed: BM (n= 10), CNS(n=2), BM and CNS (n=3), testes (n=4), and testes and CNS(n =1), Mostly they relapsed within the first 2 years after remission. In HR group, all patients (BM 3 and CNS 1) experienced relapse from 1 yr to 1 1/2 yr after initial remission.
  • 2,217 View
  • 15 Download
Close layer
Effect of Filgrastim ( rhG - CSF ) on Chemotherapy Induced Neutropenia in Pediatric Acute Myelogenous Leukemia Patients
Hee Young Shin, Hee Young Shin, Seong Hoon Hah, Hong Hoe Koo, Hyo Seop Ahn
J Korean Cancer Assoc. 1994;26(1):136-144.
AbstractAbstract PDF
To determine the safety and efficacy of rhG-CSF on chemotherapy induced neutropenia in pediatric AML patients, we conducted a prospective controlled study in 17 patiens with AML at Seoul National University Childrens Hospital from July, 1993 to January, 1994. High dose cytosine arabinoside(Ara-C, 3gm/m for four times every 12 hours) with L-asparaginase 6,000 u/m) were given to 13 patients as Group I control and after the recovery of WBC, same chemo- therapy followed by G-CSF(50 ug/m for 10 days) were given as Group I study. In Group II study, high dose Ara-C(3gm/m(2) for 8 times every 12 hours) were given to 11 patients with AML followed by G-CSF(150 ug/m for 10 days). Recovery of the absolute neutrophil counts to more than 1,000/mm' was significantly faster in the G-CSF group than in the control group(P< 0.01) and the absolute neutrophil counts on day 14 of chemotherapy was significantly higher in G-CSF group(P<0.01). The toxicity of G-CSF was minimal and there was no evidence of accel- erated growth of leukemic blasts during the G-CSF treatment. In conclusion, Filgrastim(rhG- CSF) promotes the recovery of neutrophils and shortens the duration of neutropenia induced by the chemotherapy in pediatric acute myelogenous leukemia.
  • 2,688 View
  • 21 Download
Close layer
Effects of cancer nervous System Irradiation on Neuropsychologic Functioning in Long - term Survivors of Childhood Acute Lymphoblastic Leukemia
Ji Eun Choi, Hee Young Shin, In One Kim, Kyung Mo Yeon, In Young Chae, Soo Churl Cho, Yong Seung Hwang, Hyo Seop Ahn
J Korean Cancer Assoc. 1995;27(2):303-316.
AbstractAbstract PDF
Long-term adverse neuropsychologic sequelae are frequently observed in pediatric patients treated for acute lymphoblastic leukemia(ALL). In this study, 10 children in continuous com- plete remission from ALL were given tests of IQ, neuropsychologic assessment, waking EEG, brain MRI to assess neuropsychologic functioning minimum 2 years after CNS prophylaxis. All children were free of CNS disease at diagnosis and had received CNS prophylactic treatment with 1,800 cGy cranial irradiation plus intrathecal methotrexate. Male patients had a significant decline in coding compared with female patients(P<0.01) and those evaluated beyond age of 10-year-old had a greater decline in performance IQ compared with those evaluated under age of 10-year-old(P<0.01). One of the 10 children(10%) showed white matter changes on MRI attributable to therapy. All children had no significant lower mean IQ, but lower achievement with regard to arithmetic skills, picture arrangement than other tests. We conclude that prophylactic CNS therapy may cause cognitive dysfunctions and the white matter changes but its value and significance during follow-up should be assessed in well designed longitudinal research studies.
  • 2,738 View
  • 13 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP